Flávia Castro1,2,3
Ana Patrícia Cardoso1,2
Raquel Madeira Gonçalves1,2,3
Karine Serre4
Maria José Oliveira1,2,5*
- 1i3S – Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
- 2INEB – Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal
- 3ICBAS – Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal
- 4IMM – Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
- 5Departamento de Patologia e Oncologia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal
Interferon-gamma (IFN-γ) is a pleiotropic molecule with associated antiproliferative, pro-apoptotic and antitumor mechanisms. This effector cytokine, often considered as a major effector of immunity, has been used in the treatment of several diseases, despite its adverse effects. Although broad evidence implicating IFN-γ in tumor immune surveillance, IFN-γ-based therapies undergoing clinical trials have been of limited success. In fact, recent reports suggested that it may also play a protumorigenic role, namely, through IFN-γ signaling insensitivity, downregulation of major histocompatibility complexes, and upregulation of indoleamine 2,3-dioxygenase and of checkpoint inhibitors, as programmed cell-death ligand 1. However, the IFN-γ-mediated responses are still positively associated with patient’s survival in several cancers. Consequently, major research efforts are required to understand the immune contexture in which IFN-γ induces its intricate and highly regulated effects in the tumor microenvironment. This review discusses the current knowledge on the pro- and antitumorigenic effects of IFN-γ as part of the complex immune response to cancer, highlighting the relevance to identify IFN-γ responsive patients for the improvement of therapies that exploit associated signaling pathways.
Introduction
Interferons (IFNs) are pleiotropic cytokines with antiviral, antitumor and immunomodulatory properties, being central coordinators of the immune response (1). The term “interferons” comes from the description of molecules protecting cells by “interfering” with viral infection (2, 3). Three major types of IFNs are distinguished by their sequence identity, genetic loci, cell of origin, nature, and distribution of their receptors and resulting stimuli (Table 1).
Table 1. Comparison of human type I, type II, and type III IFN production and signaling.
The human type I IFN family comprises 17 distinct proteins, mainly represented by IFN-α and IFN-β, which are ubiquitously expressed and signal through their cognate receptor, composed by IFNαR1 and IFNαR2 subunits [reviewed in Ref. (4)]. IFN-γ is the lone member of type II IFN family. It is more restrictively expressed and is structurally and functionally different from the other types of IFNs. Most recently, a type III IFN family was described to be composed of four homologous proteins (IFNλ1–4), which bind the IFNλR1 and interleukin (IL)-10Rβ heterodimeric receptor [reviewed in Ref. (8)]. To date, type I and type III IFNs have been mainly involved in host–pathogen interactions, and their expression is activated through immune system sentinel receptors, such as pattern recognition receptors. Despite the similar function of type I and III on antiviral infections, it is the viral tropism that dictates the relative contribution of each IFN (9). Moreover, whereas almost all nucleated cells respond to type I IFN, type III IFNs response is restricted to tissues with a high risk of viral exposure and infection, as the mucosal surfaces. The role of type II IFN in promoting host immune response to microorganisms is similarly well documented. Notably, it is also known to play a pivotal function on cancer immune surveillance, stimulating antitumor immunity and promoting tumor recognition and elimination (10–16).
This review focuses on type II IFN signaling, cellular functions, and directed therapies and was encouraged by novel findings revealing regulatory mechanisms of IFN-γ and its prognostic as well as therapeutic potential. In fact, since Wheelock who reported that IFN-γ inhibited viral replication in 1965 (17), it took around 30 years to envisage this cytokine as a target of antitumor immunity (18).
Interferon-gamma is a homodimer formed by the non-covalent association of two 17 kDa polypeptide subunits. During synthesis, after multiple N-glycosylation, both subunits bind in an antiparallel manner, constituting a mature 50 kDa molecule (19, 20). Notably, the IFN-γ symmetry suggests that a single molecule can bind simultaneously to two receptors, amplifying the underlying responses. Cellular responses induced by IFN-γ may also involve cross-communication with IFN-α/β receptors, amplifying IFN-γ signaling and its effects (21, 22).
Interferon-gamma is secreted predominantly by activated lymphocytes such as CD4 T helper type 1 (Th1) cells and CD8 cytotoxic T cells (23–26), γδ T cells (27–33), and natural killer (NK) cells (34, 35) and, to a less extent, by natural killer T cells (NKT), B cells (36–39), and professional antigen-presenting cells (APCs) (40–42). Its expression is induced by mitogens and cytokines, such as IL-12 (43, 44), IL-15 (45), IL-18 (46, 47), and type I IFN (48, 49). IFN-γ pleiotropic functions are mediated by cell-specific expression of hundreds of IFN-γ-regulated genes that encompass inflammatory signaling molecules, apoptosis and cell cycle regulators, and transcriptional activators (50). Autocrine IFN-γ produced by APCs can act locally and contribute to sustain self and neighbor cell activation (51–53), crucial for early control of pathogen spreading, while T lymphocytes are the major paracrine source of IFN-γ in adaptive immunity. Under physiological conditions, the constitutive expression of type I and II IFNs is tightly controlled, remaining localized to tissues, without systemic effects (54–56). For instance, constitutive expression of endogenous IFN-γ contributes to the homeostasis of immune cell functions (57), maintenance of the hematopoietic stem cell niche (58), and bone formation (59). Combination approaches to boost innate immune activation have been explored to converge onto IFN pathways. However, IFN-γ-related signaling can also have suppressive immunoregulatory effects on antiviral (60, 61), autoimmune (62, 63), as well as on antitumor responses (64, 65). Unveiling cellular targets of IFN-γ is critically important for its therapeutic application, to predict patient responses, particularly in cancers where this cytokine can exert protumorigenic effects. Therefore, the cellular and molecular effects of IFN-γ, with particular emphasis on its dual role on tumor immunity and how to overcome its limitations, will be the major focus of this review.
Canonical Signaling and Regulatory Mechanisms
The IFN-γ Receptor
The IFN-γ receptor is composed of two ligand-binding IFNγR1 chains associated with two signal-transducing IFNγR2 chains, which are responsible for connecting to the cytoplasmic transduction machinery (see Figure 1). The IFNGR1 and IFNGR2 are localized in chromosome 6 and 21, respectively, and their expression differs significantly. While IFNγR1 is constitutively expressed at moderate levels on the surface of almost all cells, IFNγR2 is constitutively expressed at low levels, and its expression is tightly regulated, according to the state of cellular differentiation or activation (66). For example, CD4 T helper cell subsets differ in their ability to respond to IFN-γ (67, 68). Remarkably, IFN-γ activates the signal transducer and activator of transcription (STAT) 1 that maintains the expression of T-bet, the master transcription factor that controls IFN-γ expression in T cells (69). This signaling constitutes a positive feedback loop that maximizes Th1 immunity (70–72). Notably, Th1 cells are more resistant to the antiproliferative effects of IFN-γ than Th2 cells. This is likely due to lower levels of expression of the IFNγR2 subunit that allows Th1 cells to continue to proliferate during IFN-γ signaling. By contrast, Th2 cells that do not produce IFN-γ express higher levels of the IFNγR2 subunit, rendering them particularly susceptible to the presence of IFN-γ that inhibits their proliferation (67, 68, 73). Nevertheless, IFNγR2 downregulation may be also induced in Th2 cells when they are exposed to IFN-γ (68). Thus, IFN-γ appears to regulate the expression of its own receptor on specific cell types, representing a regulatory mechanism of cellular desensitization in response to cytokines present at the local microenvironment. As a result, IFNγR2 expression can be a limiting factor in IFN-γ responsiveness and functional outcome that can dictate the Th1–Th2 phenotype switch and modulate the subsequent immune response.
Figure 1. Interferon-gamma (IFN-γ) canonical signaling pathway. Upon ligand binding, IFNγR1 and IFNγR2 oligomerize and transphosphorylate, activating Janus activated kinase (JAK) 1 and JAK2. These, in turn, phosphorylate IFNγR1, creating a docking site for the signal transducer and activator of transcription (STAT) 1. Phosphorylated STAT1 homodimerizes in an antiparallel configuration, forming a complex gamma-activated factor (GAF), which translocates to the nucleus and binds to gamma-activated site (GAS), located at the promoters of primary response genes, increasing their transcription. Upon induction, transcription factor interferon-regulatory factor 1 (IRF1) binds to interferon-stimulated response element (ISRE) and enhances the transcription of several secondary response genes responsible for several immunomodulatory functions. Suppressor of cytokine signaling (SOCS) proteins negatively regulate the IFN-γ pathway by inhibiting JAKs and STAT1 phosphorylation. Through dephosphorylation and deacetylation, the configuration of STAT1 homodimers reverts to parallel, triggering their exit from the nucleus.
JAK/STAT Signaling Pathway
The biological effects of IFN-γ are elicited through activation of intracellular molecular signaling networks, mainly via the JAK/STAT pathway, which modulates the transcription of hundreds of genes and mediates diverse biological responses (50, 74–76). Upon IFN-γ binding, the intracellular domains of IFNγR2 oligomerize and transphosphorylate with IFNγR1, activating the downstream signaling components, JAK1 and JAK2. The activated JAKs phosphorylate the intracellular domain of the receptor (tyrosine 440 on human IFNγR1), creating binding sites for STAT1 (77). STAT1 is then phosphorylated in the C-terminus on tyrosine Y701 residues by JAK, resulting in the formation of STAT1 homodimers complexes, known as gamma-activated factors (GAFs), which translocate to the nucleus and regulate gene expression through binding to gamma-activated site (GAS) elements in the promoters of interferon-stimulated genes (ISGs) (78). One of the major primary response genes induced by STAT1 signaling is the transcription factor interferon-regulatory factor 1 (IRF1), a member of the IFN regulatory transcription factor family (79). IRF1 functions as a transcription activator of interferon-stimulated response elements (ISRE), leading to the transcription of a large number of secondary response genes (Figure 1). For instance in breast cancer cells, a genome-wide identification of IFN-γ-induced IRF1 activation reveals over 17,000 binding sites, with “apoptosis” or “cell death” as the most enriched target processes underlying the direct tumoricidal property of the cytokine (80). However, tumor cells also develop resistance to IFN-γ through differential IRF1 responsiveness, pointing out that the JAK/STAT signaling pathway needs to be tightly regulated to avoid detrimental consequences of excessive stimulation and highlighting its role on immune responses and tumorigenesis (81). STAT1 targets of the IFN-γ-mediated signaling also include the SMAD family member 7 (SMAD7), and proteins involved in cell cycle regulation, such as c-Myc and the cyclin-dependent kinase inhibitor 1A (82–84).
The JAK/STAT signaling pathway is regulated at several levels by positive and negative mechanisms. In particular, deregulation or inhibition of the JAK/STAT pathway leads to lowered immunity and is often associated with increased tumorigenesis (85, 86) or metastatic dissemination (87). STATs are also involved in the development and function of the immune system and play a role in maintaining tumor surveillance [reviewed in Ref. (88)]. STAT1, as a tumor suppressor, is deducted for its expression in tumor cells, modulates their immunological status and consequently their response to antitumor immune responses. Indeed, STAT1-deficient tumor cells were more susceptible to NK cells while STAT1-proficient tumor cells were more sensitive to CD8+ T cells (89). In the same way, STAT1-deficient mice that are impaired in Th1 cell polarization, exhibited reduced IFN-γ expression and compromised cytolytic and NK lytic activity, failing to control tumor growth in contrast with wild-type mice (90). In addition, cell-autonomous tumor-suppressor functions of STAT1 have also been reported in breast cancer (91). However, there is growing evidence that STAT1 also acts as a tumor promoter (92–94) since it can enhance resistance to chemotherapeutic agents and radiation in carcinoma (95). Importantly, STAT1 also participates in the signaling from different cytokines, including IL-21, IL-27, and IL-35. These cytokines have been proposed to limit antitumor immunity in specific cellular, molecular, and microenvironmental contexts (96–101). Thus, STAT1 phosphorylation reflects not only the threshold and magnitude of IFN-γ response but also of other immune mediators, highlighting the importance of the regulation of STAT1 phosphorylation. One of the most important negative regulators of the JAK/STAT signaling pathway is the suppressor of cytokine signaling (SOCS) proteins, which expression is increased in response to IFN-γ signaling through IRF1 (102, 103). SOCS blocks the activity of JAKs by a negative feedback loop, but also regulates other cytokines downstream signaling. SH2 domains in SOCS proteins directly bind to phosphorylated tyrosine residues of activated JAKs, blocking the recruitment of signal transducer adaptors, such as STATs, and JAK activity (102). Furthermore, SOCS promote interactions that lead to ubiquitination and proteasome degradation of components of the JAK/STAT signaling (104, 105). SOCS1 even prevents regulatory T (Treg) cells from producing IFN-γ by suppression of STAT1, avoiding the conversion of Treg cells into effector cells (106). In addition, SOCS2-deficient mice showed a reduction in lung metastases and an increase in survival following melanoma challenge (107).
Alternatively, the transcriptional activity of STAT1 can be positively regulated by other signaling cascades triggered by IFN-γ binding, such as the mitogen-activated protein kinase pathway, protein kinase C, and PI3K/AKT, which phosphorylate STAT1 in its transactivation domain (108). Adding to the complexity, under certain circumstances, IFN-γ also can activate STAT1-independent pathways through other transcription factors, namely STAT3 (109), STAT5 (110), nuclear factor-kappa B (NF-κB) (111), and activator protein 1 (112). In conclusion, the primary response of IFN-γ is mediated by GAF that acts on genes with GAS binding sequence in their promoter, while the primary response of type I IFNs is mediated by ISGF3 (STAT1/STAT2/IRF9 complex) that induces genes that have ISRE in their promoter. Thus, some of the ISGs are regulated by both types of IFNs, whereas others are selectively regulated by each type of IFN, consequently potentiating the diversity of biological responses.
Biological Functions
IFN-γ Actions on Immune Cells
Interferon-gamma signaling pathway coordinates several biological responses, primarily involved in host defense and immune surveillance but also in the establishment of adaptive immunity (Figure 2) and in the regulation of inflammation, apoptosis and cell cycle. One of the first described biological effects of IFNs was the upregulation of the major histocompatibility complex (MHC) molecules (113, 114) as well as the upregulation of the whole MHC I and II antigen processing and presentation machinery including transporter associated with antigen processing (TAP) 1/2, invariant chain, and the expression and activity of the proteasome (115–122). Furthermore, in some tumor types, such as multiple myeloma and melanoma cells, IFN-γ can also upregulate the MHC class II transactivator (CIITA) that leads to MHC class II expression (123, 124). Thus, IFN-γ initiates an immune-antigenic exposure program in the target cells, and this ensures the rapid recognition of stressed tissues. IFN-γ is a major product of Th1-mediated immune response and orchestrates Th1 effector mechanisms, as further activation of innate immunity (macrophages and NK cells) in a positive feedback loop. Upregulation of cell surface MHC class I by IFN-γ is crucial for host response to intracellular pathogens and tumor cells, due to cytotoxic T cell activation, promoting cell-mediated immunity. IFN-γ directly acts as a cytotoxic CD8 T cell differentiation signal, and it is essential for the induction of cytotoxic T cell precursor proliferation (125, 126). IFN-γ also upregulates cell surface MHC class II on APCs, thus promoting peptide-specific activation of CD4 T cells (25, 127–129). In addition, IFN-γ activates macrophages toward a pro-inflammatory profile, exhibiting an increased phagocytic ability as well as enhanced microbial killing activity (130). In fact, IFN-γ was initially shown to induce “classical” activation of macrophages and polarization toward a tumoricidal phenotype (131). Interestingly, the original name of IFN-γ was macrophage activation factor (132, 133). IFN-γ controls specific gene expression programs involving more than 290 genes related to cytokine and chemokine receptors, cell activation markers, cellular adhesion proteins, MHC proteins, proteasome formation, protein turnover, and signaling mediators and regulators (134). The ability of IFN-γ to induce tumor cell killing includes the activation of the NADPH-dependent phagocyte oxidase system, nitric oxide production, tryptophan depletion and upregulation of lysosomal enzymes (121, 135, 136). These events result in recruitment of effector cells to help in the inflammation resolution process (137, 138). In addition, as a major cytokine of Th1 cells, IFN-γ maintains Th1 lineage commitment through a positive feedback loop that stabilizes the Th cell phenotype (72, 139–141) and cross-inhibits the differentiation to other Th cell subsets (Figure 2). Indeed, IFN-γ inhibits Th2 cell differentiation (142, 143) and consequently IL-4 production. This regulation involves the inhibition of the IL-4/STAT6 pathway, required for Th2 cell differentiation, and it is mediated at least by IFN-γ-induced SOCS1 that inhibits IL-4R signaling (144, 145). Furthermore, IFN-γ-induced T-bet inhibits Th2 cell differentiation by directly interfering with the activity of Th2 cell-specific transcription factor, GATA-3 (146). Höfer and colleagues, using mathematical models, proposed that IL-4 also acts to propagate Th2 cell differentiation (147). A high IL-4 level promotes increased GATA-3 expression that further enhances GATA-3 transcriptional imprinting for Th2 differentiation (147, 148). This model proposed that high expression state of GATA-3 can be suppressed by strong inhibition of autoactivation, as observed in the presence of Th1-polarizing conditions (147, 149). IFN-γ was also described to downregulate the IL-4-inducible gene expression (150). The cross-regulation of Th1 and Th2 cells was also demonstrated in STAT6-deficient mice, which lack Th2 phenotype and associated immune responses. These animals displayed augmented tumor-specific IFN-γ production and cytotoxic T cell activity and, consequently rejected the tumor cell line that grew progressively in the wild-type control (151).
Figure 2. Immunomodulatory effects of interferon-gamma (IFN-γ). IFN-γ produced by immune cells affects the behavior of distinct immune cells within the tumor microenvironment. Specifically, IFN-γ plays a major role in activating anticancer immunity, by promoting the activity of CD4 T helper type 1 cells, CD8 cytotoxic T lymphocyte (CTL), natural killer (NK) cells, dendritic cells (DCs), and macrophages, promoting the antigen presentation. Additionally, IFN-γ activates macrophages towards a more pro-inflammatory and tumoricidal phenotype (M1-like). Alternatively, IFN-γ inhibits regulatory T (Treg) cells, Th2 and Th17 differentiation and functions.
Interferon-gamma produced by Th1 cells also counteracts Th17 cell development and their effector functions (152–154). Several mechanisms can be considered as the inhibition of molecules involved in the Th17 differentiation (155, 156), the inhibition of STAT3 by STAT1 (157) and recently, T-bet was demonstrated to prevent differentiation of Th precursors into Th17 cells by blocking the expression of the Th17 cell lineage-specific transcription factor, RORγt (158). Furthermore, IFN-γ also exerts regulatory functions to limit tissue damage associated with inflammation (63, 159–162) (Figure 2). IFN-γ has been classically considered as a pro-inflammatory cytokine, involved in the regulation of anti-inflammatory responses, by antagonizing the IL-10 (157, 163) and TGF-beta (164) signaling pathways. Consequently, IFN-γ inhibits Treg cell differentiation and functions (165, 166). However, in some chronic inflammation conditions, IFN-γ plays a crucial role in attenuating tissue destruction. In this case, IFN-γ might be protective (62, 167) by promoting the number and function of Treg cells (168–170). In addition, IFN-γ production by Treg cells themselves was shown to be a key feature of the Treg cells that are capable of dampening Th1 cell responses (171–174). Thus, IFN-γ dictates the differentiation of specialized Foxp3+T-bet+ Treg cells that selectively suppress Th1 cells, and constitute a negative feedback loop to minimize the detrimental effect of IFN-γ. IFN-γ also promotes the differentiation of myeloid-derived suppressor cells (MDSCs) that restrain overactivation of effector T cells, maintaining tissue homeostasis (175, 176). Other regulatory mechanisms involving IFN-γ signaling that dampen the magnitude of the immune response have been reported, as the induction of indoleamine 2,3-dioxygenase (IDO) by Treg cells, monocytes and stromal cells (177–180), and of the programmed cell death 1 (PD-1) ligand (PD-L1) on immune and transformed cells, inhibiting T cell responses (181–183).
IFN-γ Actions on Transformed Cells and on the Tumor Microenvironment
Interferon-gamma is involved in antiproliferative (18), antiangiogenic (184) and pro-apoptotic effects established against neoplastic cells. How IFN-γ induces the signaling pathways initiating and propagating the apoptotic cascade remains to be elucidated. The level of complexity is demonstrated by the fact that the mechanism might depend on the tumor cells themselves. For example, while in a glioblastoma cell line the induction of apoptosis was due to suppression of the PI3K/AKT pathway, in another glioblastoma cell line apoptosis occurred independently of the PI3K/AKT pathway but required NF-κB (185). It was also shown that IFN-γ induces apoptosis of human pancreatic carcinoma cells in a caspase-1-dependent manner (186). A review covered in detail the mechanism of induction of programmed cell death (187). So far, the known biological functions of IFN-γ indicate that, although it can act as a potent inducer of antitumor immunity, it actually has a dual role and may also favor tumor immune evasion.
IFN-γ in Cancer
The first reports pointing to the relevance of IFN-γ in antitumor immunity came from studies with the fibrosarcoma (Meth A) cell line, refractory to IFN-γ signaling, since it lacks the expression of the IFNγR1 subunit. IFN-γ-insensitive Meth A cells displayed enhanced tumorigenicity compared with control cells and were not rejected in syngeneic tumor mice models, suggesting that IFN-γ plays an important role in tumor cell elimination (18). This finding was further supported by experiments using 129/SV IFN-γ insensitive mice, lacking the IFNγR1 subunit or STAT1, which developed 3-methylcholanthrene (MCA)-induced sarcomas more rapidly and more frequently than their wild-type counterparts (12). Similarly, these IFN-γ-insensitive mice lacking the tumor-suppressor protein p53 formed spontaneous tumors more rapidly than IFN-γ-sensitive p53-deficient mouse (12). In addition, C57BL/6 mice that lack the gene encoding IFN-γ also displayed higher susceptibility to experimental (B6, RM-1 prostate carcinoma) and spontaneous (BALB/c, DA3 mammary carcinoma) models of primary and metastatic tumors (13, 14). Notably, further studies described that IFN-γ may cooperate with other molecules to prevent tumor formation. Mice deficient in both granulocyte/macrophage colony-stimulating factor (GM-CSF) and IFN-γ developed lymphoma and non-lymphoid solid tumors at a higher rate than did mice deficient in GM-CSF or IFN-γ alone (15). Additional studies revealed that mice insensitive to IFN-γ, or that lack the recombination activating gene (RAG) protein (failing to produce mature B and T lymphocytes), or that lack both, showed similar incidence of MCA-induced sarcomas, suggesting that the T cell–IFN-γ axis is involved in immune surveillance (10).
The role of IFN-γ on cancer immunoediting emerged from studies assessing the immunogenicity of tumors from immunocompetent versus immunodeficient mice. Kaplan et al. showed that MCA-induced sarcoma cells from IFNγR1-deficient mice (unresponsive to IFN-γ signaling) grow as aggressively in immunocompetent as in IFNγR1-deficient mice. However, when IFN-γ responsiveness was conferred on the tumor cells by introducing the IFNγR1 subunit, they became more immunogenic and were rejected through a T cell-dependent manner (12). This constitutes the first demonstration that IFN-γ sensitivity of the tumor is fundamental for an efficient antitumor response. Other studies revealed that wild-type hosts rejected 40% of MCA-induced sarcomas derived from RAG2-deficient mice, showing that these tumors were more immunogenic than those from wild-type mice (10). In addition, human tumors were evaluated for their ability to upregulate MHC I expression in response to IFN-γ stimulation. These studies revealed that 33% of 33 melanoma tumor cell lines showed a reduction in IFN-γ sensitivity while 4 of 17 lung adenocarcinoma cell lines were totally unresponsive to IFN-γ (12). This lack of response resulted from cellular defects on IFNγR1 and of JAK proteins and may explain the ability of many tumor cells to evade the immune response. Recently, JAK1/2 deficiency was demonstrated to protect melanoma cells from antitumor IFN-γ activity and results in T-cell-resistant melanoma lesions (188). Others reported the lack of STAT1 in melanoma cell lines and in some chronic myeloid leukemia cells (189). Furthermore, DNA methylation that selectively represses CIITA, in colorectal and gastric cancer cell lines, was associated with the absence of IFN-γ-induced HLA-DR, suggesting that this epigenetic alteration of CIITA enables some gastrointestinal cancer cells to evade the immune system (190). Concomitantly, epigenetic alterations repressing MHC2TA were described in T cell leukemias, B cell lymphomas, and in several cancer cells, such as small cell lung cancer and neuroblastoma cells that were unable to express MHC II upon IFN-γ stimulation (191–194). Consistently, IFN-γ upregulates CIITA expression on multiple myeloma and melanoma cells increasing their MHC II expression (123, 124). These findings indicate that IFN-γ acts on tumor cells, enhancing their recognition by CD8 T cells as well as by CD4 T cells, and unveiling a key role in the promotion of tumor immunogenicity. Altogether, these works pave the way for the elaboration of the stepping-stone concept of immunoediting promoted by IFN-γ (195, 196).
IFN-γ-Mediated Mechanisms Underlying Antitumorigenic Effects
As described earlier, the mechanisms by which IFN-γ exerts its antitumor effects depend on multiple processes. IFN-γ is described as an antiproliferative agent that regulates the expression of cyclin-dependent kinase inhibitor 1 (p21) through STAT1 activation in tumor cells (84, 197). Moreover, IFN-γ is able to promote tumor cells apoptosis by upregulating the expression of caspase-1, -3, -8 (198, 199) and by enhancing the secretion of FAS and FAS ligand (200) and TNF-related apoptosis-inducing ligand (201, 202). Recent studies showed that IFN-γ also induces its tumoricidal effects through a form of regulated necrotic death (also named as necroptosis) that relies on the activity of the serine–threonine kinase RIP1 (203). Importantly, IFN-γ is also involved in the inhibition of angiogenesis, impairing the proliferation and survival of endothelial cells, inducing ischemia in the tumor stroma (184, 204, 205). In particular, IFNγR is expressed on blood endothelial cells and engagement of the receptor results in blood vessel destruction and necrosis, an important mechanism that leads to tumor rejection (206).
Considering the effect of IFN-γ on the host immune cells present at the tumor microenvironment, major efforts have been made for the development and establishment of combined clinical therapeutic applications (90, 151, 207). IFN-γ is critical for T cell, NK and NKT cell trafficking into the tumors through CXCL9, CXCL10, and CXCL11 chemokine induction (208, 209). Accordingly, T cells fail to migrate to tumor site in IFNγ-deficient mice (65). In commitment, dipeptidylpeptidase 4 inhibition, a protease that inactivates these chemokines, enhanced tumor rejection by increasing lymphocytes trafficking into the tumor (210). Lately, galectin-3 secreted by several tumors was demonstrated to bind glycosylated IFN-γ at the tumor extracellular matrix, avoiding IFN-γ diffusion and the formation of an IFN-γ-induced chemokine gradient required for T cell recruitment and infiltration (211). In addition, CXCL10 also prevents tumor angiogenesis by blocking endothelial cell proliferation (212) and consequently a decrease in microvessel density as observed in melanoma tumor xenografts (213). Apoptosis of endothelial cells by IFNs causes restriction of blood flow within the tumor vasculature, leading to tumor shrinkage (214). This is an effect of IFN-γ, not directly targeted to the tumor cell, but to the tumor vasculature, with drastic and desirable effects on tumor growth. A recent report also showed that IFN-γ was essential for the initial priming and differentiation of cytotoxic T cells residing in the periphery of the eye, contributing to the regression of intraocular tumors (215). Supporting data from therapy models showed that IFN-γ induces survivin and ifi202, two genes involved in T cell maturation, survival, and proliferation, in tumor-specific T cells (216). Overall, these studies demonstrated the relevance of IFN-γ on T cell-mediated antitumor immunity.
Interferon-gamma is also involved in macrophages tumoricidal activity (217). This cytokine supports a CD4 T cell/macrophage effector axis which acts as immune surveillance mechanism for MHC II-negative cancer cells (25). Indeed, upon recognition of tumor antigens present in the context of MHC II by macrophages, CD4 T cells secrete IFN-γ that further activates macrophages in the tumor, leading to tumor growth inhibition (25). This collaboration between CD4 T cells and macrophages was also essential for successful cancer immune surveillance in non-solid cancers, as myeloma and B-cell lymphoma. Indeed, Th1-secreted IFN-γ was shown to trigger a cytotoxic activity of tumor-associated macrophages (TAMs) and also induces CXCL9/MIG and CXCL10/IP-10 secretion by macrophages, which may affect the tumor progression by angiogenesis inhibition (129). IFN-γ-activated macrophages also acquire a tumoricidal phenotype with the upregulation of cytotoxicity-associated markers including granzyme A/B, and NKG2D (129). In addition, in STAT6-deficient mice, that display increased levels of IFN-γ, rejection of metastatic disease after removal of the primary tumor involved the generation of pro-inflammatory macrophages, also termed M1-like macrophages, and a decrease in MSDCs that accumulated during primary tumor formation (218). Studies from APCMin/+ mice (that are highly susceptible to spontaneous intestinal adenoma formation) lacking IFN-γ signaling showed an accumulation of TAMs, more prone towards protumoral (M2-like) polarization, and upregulation of matrix metalloproteases. These results suggest that IFN-γ unresponsiveness contributes to the creation of an anti-inflammatory microenvironment, favorable to intestinal tumorigenesis (219). The properties of IFN-γ to reverse the myeloid immunosuppressive functions were also demonstrated in protumor role of human ovarian TAMs (220) and human M2-like macrophages (221).
Importantly, IFN-γ has also a key role on IL-12 production, supporting the activity of this later cytokine in cancer immune surveillance (222–225). Indeed, exogenous IL-12 administration into fibrosarcoma-bearing mice resulted in a complete tumor regression (222). This observation was extended to primary tumorigenesis models treated with exogenous IL-12 (226, 227). Consistent with this, chimeric antigen receptor-redirected T cells engineered to produce IL-12 where found to secrete increased IFN-γ levels and to display enhanced antitumor cell activity (228–230).
Regarding the importance of IFN-γ in cancer diagnostics, IFN-γ-associated signatures have a predictive value in cancer immune phenotypes (81, 231, 232). In addition, IFN-related gene signature is a predictive marker for chemotherapy and radiotherapy efficiency for breast cancer (94) as well as to PD-1 or cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade in various types of malignancies (233–235). Consistently, immunotherapy using immune checkpoint blockers (anti-CTLA-4 and/or anti-PD-1) combined with anticancer vaccines, clearly associate inhibition of tumor growth with increased proportion of IFN-γ-producing effector T cells (236, 237). This is also verified in clinical trials, through which the anti-CTLA-4 therapy was associated with an increase of IFN-γ-producing ICOS+ (inducible costimulatory) CD4 T cells and of T effector/Treg cell ratio in bladder cancer samples (238). In addition, PD-1 blockade was demonstrated to enhance T cell infiltration by promoting IFN-γ-inducible chemokines (239). In other way, it was recently shown that IFN-γ-induced Treg cell fragility (loss of suppressive function) is required for response to anti-PD-1 therapy (240).
Altogether, the versatility of IFN-γ and its fine-tuned biological effects highlight its relevance for therapeutic applications, and some clinical trials have already encouraging results. In fact, 75% of metastatic melanoma patients were non-responders to anti-CTLA-4 therapy, and this was associated with genomic defects of IFN-γ signaling genes on tumors (241). Recently, apelin receptor (APLNR) was described to regulate JAK/STAT signaling, modulating IFN-γ responses. Multiple loss-of-function mutations in APLNR were identified in patient tumors refractory to immunotherapy (242). The inclusion of IFN-γ in the first-line treatment of ovarian cancer resulted in benefit regarding progression-free survival, with acceptable toxicity (243). IFN-γ treatment also appears to be effective against bladder tumors by recruitment and activation of intratumoral leukocytes (244). In a phase I clinical trial, which combined adoptive T cell therapy with intralesional administration of adenovirus expressing IFN-γ in metastatic melanoma, 38.5% of the patients had an overall objective response and 46% were able to control the disease (245).
IFN-γ-Mediated Mechanisms Underlying Protumorigenic Effects
It is becoming increasingly clear that IFN-γ can exert certain effects supporting tumorigenesis. Immune evasion can operate through tumor cells losing responsive to IFN-γ signaling to avoid its antiproliferative, pro-apoptotic, and immunoregulatory actions. This has been demonstrated with the tumor cells losing the receptor for IFN-γ or a component of JAK/STAT signaling (12, 18). In addition, constitutive activation of inhibitory molecules of this pathway, as SOCS1 and SOCS3, limits the actions of IFNs on human melanoma cells (246) and favors the activation of alternative signaling pathways, as STAT3, which is associated with tumor progression (247). These evidences suggest that tumor cells develop IFN-γ-dependent strategies to evade the immune system, leading to the emergence of very aggressive tumors, which are on the basis of immunoediting. In 2011, Zaidi and Merlino proposed that IFN-γ actions might play a physiological role in protecting cells from damage in a setting of tissue remodeling and repair, while on cells harboring oncogenic mutations, the same mechanisms may prevent cell destruction and allow complete transformation (248). Consistent with this, NF-κB in tumor cells was shown to act as a protective mechanism against IFN-γ-induced necroptosis (203).
Indeed, there are significant evidences that tumor cells can take the advantage of IFN-γ as an inducer of anti-inflammatory responses and protumor effects. The first report of the negative potential effects was in 1987 by Taniguchi and colleagues who proposed that IFN-γ changes the metastatic ability of the B16 melanoma cells in a cell-autonomous manner (249). Data from experiments using the CT26 colon carcinoma model showed that IFN-γ promotes tumor escape through the downregulation of the endogenous tumor antigen gp70 (250). IFN-γ expression by human melanoma samples was associated with enhanced expression of MHC class II molecules and the acquisition of a more aggressive phenotype (251, 252).
One of the principal mechanisms of tumor immune escape is the suppression of cytotoxic T cells and of NK cell-mediated immune responses. Brody and colleagues showed that IFN-γ upregulates IDO in melanoma cells and recruits Treg cells to avoid immune recognition (253). Curiously, IFN-γ induced IDO competence on human monocyte-derived DCs but had no effect on pro-inflammatory cytokine release, suggesting that IFN-γ triggers IDO activity and pro-inflammatory cytokine release as distinct cellular programs. In addition, IDO-competent DCs induced regulatory activity on allogeneic T cells (179). IFN-γ was also described to be involved in the accumulation of MDSCs in inflamed liver, which leads to T cell suppression (254). MDSCs producing nitric oxide decreased IFN-γ responsiveness of immune cells, such as T and NK cells (255).
One important aspect is the ability of IFN-γ to induce PD-L1 expression in cancer, stromal and myeloid cells to impair effector tumor immunity (181). Abiko and colleagues demonstrated that the contact between tumor cells and CD8 T cells is necessary for the induction of PD-L1, underlying the importance of paracrine exposure to IFN-γ (256). Recent reports suggest that loss of IFN-γ pathway genes, such as JAK1 and JAK2, is associated with resistance to anti-PD-1 therapy (257, 258). Prolonged IFN-γ signaling in tumors was also shown to coordinate PD-L1-dependent and PD-L1-independent resistance to immune checkpoint blockade and to other therapeutic combinations, such as radiation and anti-CTLA-4, through a multigenic resistance program (259). In addition, other inhibitory pathways are reinforced by IFN-γ, including CTLA-4 and CD86/CD80 interaction (260).
Interferon-gamma was used in clinical trials for melanoma but no significant improvement for patients was observed (261–264). In fact, IFN-γ treatment had no contribution to the outcomes of patients with metastatic renal cell carcinomas (265), leukemia (266), pancreatic carcinoma (267), breast cancer (268), or into the postoperative surgical therapy for colon cancer (269). Furthermore, a phase 3 trial of IFN-γ plus standard treatment with carboplatin/paclitaxel versus carboplatin or paclitaxel alone, for treated advanced ovarian tumors, was early terminated due to a higher incidence of serious hematological toxicities in patients receiving combined therapy compared with chemotherapy alone (270). The failed attempts to treat cancer patients with exogenous IFN-γ raised several concerns: the absence of tumor immunogenicity, the lack of IFN-γ-signaling components, the upregulation of IFN-γ signaling inhibitors, the immunosuppressive tumor microenvironment, the lack of effector T cells, or presence of anergic T cells and, in some cases toxicity. These accumulating evidences reinforce the importance to determine the grade of patients’ IFN-γ-responsiveness. For example, in cases with low IFN-γ actions, active immunization either via IFN-γ treatment or via adjuvants of the immune system, as toll-like receptor ligands, should be considered, as demonstrated recently by using bacterial outer membrane vesicles that eradicate established tumors in an IFN-γ-dependent mechanism (271). The combination with radio- and chemotherapy is expected to be useful through immunogenic cell death that also elicits the innate immune system. Promising results were obtained with combination of low-dose 5-fluorouracil with recombinant interferon-gamma (IFN-γ) in patients with advanced hepatocellular carcinoma (272). In cases with high levels of IFN-γ signaling, the therapy with anti-PD-1/anti-PD-L1 is expected to be important.
Overall, these findings indicate that the local immune microenvironment of tumors is complex and variable and that for an effective therapy it is essential to evaluate, individually, the immune profile of patients or immune contexture [reviewed in Ref. (232, 273)], taking into account that it may evolve and modify throughout the anticancer therapy (Figure 3).
Figure 3. Dual face of interferon-gamma (IFN-γ) in tumor immunity. IFN-γ can display both antitumor and protumor activities. Under both circumstances, IFN-γ influences tumor cells directly and indirectly, by activation of immune cells. The antitumor effects comprise the development, recruitment, and activation of innate immune cells as well as the activation and maintenance of effector T cells. The antitumor effects of IFN-γ result in direct inhibition of tumor proliferation, recognition, and elimination. In other way, the protumorigenic role of IFN-γ involves proliferative and antiapoptotic signals, as well as escape of the tumor cells from recognition and cytolysis by cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. The broad range of IFN-γ actions depends on the context of tumor specificity, IFN-γ-signaling intensity, and other microenvironment conditions.
IFN-γ in Therapy—Where are We and Where are We Going?
Interferon-gamma therapy has ensued in clinical applications approved by the Food and Drug Administration in the treatment of chronic granulomatous disease, in 1999 and severe malignant osteopetrosis, in 2000. Despite the promising therapeutic applications of IFN-γ in several settings, its limited success in cancer-immunotherapy trials might be due to cancer cell unresponsiveness to this cytokine, the failure to deliver it locally or with the adequate periodicity to achieve a therapeutic effect. Moreover, IFN-γ clinical use has also been restricted due to several limitations inherent to its molecular properties. Essentially, these include stability problems, such as acid degradation, and also the tendency to aggregate irreversibly under mild denaturing conditions, with subsequent loss of biological activity [the pharmacological aspect of IFN-γ is reviewed in Ref. (274, 275)]. Furthermore, IFN-γ is rapidly cleared from the blood when administered intravenously (276), requiring frequent re-administrations of high cytokine concentrations, to elicit an effective response at the target site, leading to systemic toxicity and side effects, such as fever, fatigue, nausea, vomiting, diarrhea, neurotoxicity, and leukopenia (277). These adverse effects are caused mainly by high serum concentration of the protein, due to an unequal distribution between body fluids and tissues (276) and, additionally, to the ubiquity of receptors which are expressed at the membrane of the majority of human cells (278, 279) and also to the existence of a circulating soluble form (which function remains elusive) (280).
These constraints in the clinical use of IFN-γ have encouraged the development of alternative delivery methods with the purpose of achieving higher therapeutic outcomes and, simultaneously, weaken its toxicity. Numerous reports have focused mainly on efficient routes of delivery rather than on systemic applications (281–287). In fact, IFN-γ is naturally produced in a paracrine manner, with local secretion and diffusion to the surrounding cells and microenvironment throughout the extracellular fluids (288). Therefore, a localized delivery of this cytokine has been determined to be more appropriated in terms of therapeutic efficiency, due to its specific effect at the target site, while simultaneously intensifying the intended cytotoxic effects and immunological stimulation (289). In particular, tumors can be rejected by local IFN-γ expression, but rejection of established tumors was less efficient over time, suggesting that timing of treatment plays a critical role, for transplanted tumors became less susceptible to local IFN-γ treatment the better they are established (206). Another relevant aspect concerns the mode of administration, being it an intermittent or sustained release. Several studies concluded that a sustained release strategy is more efficient by limiting the exposure of other cells and organs to the deleterious effects of high IFN-γ concentrations (290–295). In the particular case of cancer immunotherapy, consistent findings show that a stable and high concentration at the target site is required to elicit an effective response (288, 296), prompting several attempts to promote local delivery of IFN-γ with controlled release. These include liposomes, polymer gels, biodegradable microspheres, gene therapy, and magnetic or albumin nanoparticles (285, 297–301). However, these strategies revealed unsuccessful by failing to maintain a stable and/or bioactive cytokine prior release, an inadequate release rate, a labor intensive and cost ineffective manufacture, and safety issues. Oncolytic viruses have gained interest for immunotherapy due to their ability to selectively destroy tumor cells and to their potential to stimulate antitumor immunity. Oncolytic vesicular stomatitis virus expressing IFN-γ demonstrated greater activation of DCs, higher pro-inflammatory cytokines’ secretion, and reduced tumor growth in 4T1 tumor model compared with the parental virus, suggesting that specific production of the IFN-γ within the tumor microenvironment is beneficial for the antitumor immune response (302). Recently, an IFN-γ-delivery system based on chitosan/poly(γ-glutamic acid) polyelectrolyte complexes was described by our group to successfully decrease macrophage-derived stimulation of cancer cell invasion in vitro through the modulation of a pro-inflammatory macrophage phenotype (221). In fact, several efforts have been directed to educate APCs toward an immunostimulatory and antitumor phenotype (Figure 4) (303–306). In another work, a silk-based hydrogel was designed to regulate cytokine delivery for macrophages, which are actively involved in tissue remodeling and vascularization, with the aim to regulate the microenvironment of biomedical implants (307). Other potential strategy to improve the shorter half-live of IFN-γ is fusing it with antibodies, enhancing its stability in the serum and tumor target specificity and reducing toxic side effects (308). Although promising results have been achieved with some of these strategies, the desired requirements are yet to be accomplished and need further investigation/development.
Figure 4. Modulation of antigen-presenting cells (APCs) profile as anticancer therapeutic strategies. The tumor microenvironment is frequently immunosuppressive with APCs functions compromised, and consequently with poor T cell response. As APCs can be modulated by microenvironmental signals, these cells are promising targets. Interferon-gamma (IFN-γ) and other molecules can be used to re-educate tumor-associated macrophages, frequently associated with anti-inflammatory status (M2-like) toward a pro-inflammatory and antitumor profile, while stimulating regulatory dendritic cells (DCs) to an immunostimulatory profile. This stimulation can potentiate effector T cell response and inhibit tumor progression.
Concluding Remarks
Herein, we discussed the role of IFN-γ on tumor immunity and its potential therapeutic implications. On one side IFN-γ appears as a promoter of tumor immune surveillance and on the other as a supporter of tumor escape. The outcome of IFN-γ signaling depends on the tumor-specific context, the magnitude of the signal, and the microenvironmental cues. Nevertheless, IFN-γ or IFN-γ inducers remain promising agents to include in combined therapies against cancer. We believe that the effectiveness of future IFN-γ-based therapies will involve the development of systems to deliver the appropriate amount of cytokine to target cells, minimizing its side effects. In addition, these strategies would profit from the combination with conventional treatments and with anti-PD-L1 and anti-CTLA-4 therapies to overcome the regulatory effects of IFN-γ. Another important issue is to consider a personalized approach, which takes into account the patient responsiveness to IFN-γ, by using predictive biomarkers, as IFNγR2, SOCS, APLNR, STAT1, or STAT3. Thus, a comprehensive understanding of the complex and variable tumor microenvironment, as well as a deeper evaluation of the immune, vascular and stromal profile, will be necessary for the stratification of cancer patients and for the establishment of efficient personalized therapies.
Author Contributions
FC performed the initial draft, written the manuscript, and designed Figures 2–4. AC written a part of Section “IFN-γ IN Therapy—Where Are We and Where Are We Going?” and performed Figure 1. RG, KS, and MO critically revised the manuscript, reorganized ideas, and approved the final version.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
This article is a result of the project NORTE-01-0145-FEDER-000012, supported by Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF) and through the FCT PhD Programmes by Human Capital Operational Programme (POCH), specifically by the BiotechHealth Programme. FC and RG, KS, and MO also acknowledge FCT for PhD grant (PD/BD/114013/2015) and for the FCT Investigator Grants (IF/00638/2014, IF/00004/2014 and IF/01066/2012), respectively. AC has a postdoctoral fellowship (POCI-01-0145-FEDER-016390). KS received an iMM Laço-2016 research grant.
References
1. Gresser I. Biologic effects of interferons. J Invest Dermatol (1990) 95:66S–71S. doi:10.1111/1523-1747.ep12874776
2. Nagano Y, Kojima Y. [Immunizing property of vaccinia virus inactivated by ultraviolets rays]. C R Seances Soc Biol Fil (1954) 148:1700–2.
3. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci (1957) 147:258–67. doi:10.1098/rspb.1957.0048
4. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol (2014) 14:36–49. doi:10.1038/nri3581
5. de Weerd NA, Samarajiwa SA, Hertzog PJ. Type I interferon receptors: biochemistry and biological functions. J Biol Chem (2007) 282:20053–7. doi:10.1074/jbc.R700006200
6. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol (2004) 75:163–89. doi:10.1189/jlb.0603252
7. Saha B, Jyothi Prasanna S, Chandrasekar B, Nandi D. Gene modulation and immunoregulatory roles of interferon gamma. Cytokine (2010) 50:1–14. doi:10.1016/j.cyto.2009.11.021
8. Wack A, Terczynska-Dyla E, Hartmann R. Guarding the frontiers: the biology of type III interferons. Nat Immunol (2015) 16:802–9. doi:10.1038/ni.3212
9. Pott J, Mahlakoiv T, Mordstein M, Duerr CU, Michiels T, Stockinger S, et al. IFN-lambda determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci U S A (2011) 108:7944–9. doi:10.1073/pnas.1100552108
10. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 410:1107–11. doi:10.1038/35074122
11. Wang L, Wang Y, Song Z, Chu J, Qu X. Deficiency of interferon-gamma or its receptor promotes colorectal cancer development. J Interferon Cytokine Res (2015) 35:273–80. doi:10.1089/jir.2014.0132
12. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 95:7556–61. doi:10.1073/pnas.95.13.7556
13. Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood (2001) 97:192–7. doi:10.1182/blood.V97.1.192
14. Street SE, Trapani JA, MacGregor D, Smyth MJ. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med (2002) 196:129–34. doi:10.1084/jem.20020063
15. Enzler T, Gillessen S, Manis JP, Ferguson D, Fleming J, Alt FW, et al. Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J Exp Med (2003) 197:1213–9. doi:10.1084/jem.20021258
16. Mitra-Kaushik S, Harding J, Hess J, Schreiber R, Ratner L. Enhanced tumorigenesis in HTLV-1 tax-transgenic mice deficient in interferon-gamma. Blood (2004) 104:3305–11. doi:10.1182/blood-2004-01-0266
17. Wheelock EF. Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin. Science (1965) 149:310–1. doi:10.1126/science.149.3681.310
18. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity (1994) 1:447–56. doi:10.1016/1074-7613(94)90087-6
19. Kelker HC, Le J, Rubin BY, Yip YK, Nagler C, Vilcek J. Three molecular weight forms of natural human interferon-gamma revealed by immunoprecipitation with monoclonal antibody. J Biol Chem (1984) 259:4301–4.
20. Ealick SE, Cook WJ, Vijay-Kumar S, Carson M, Nagabhushan TL, Trotta PP, et al. Three-dimensional structure of recombinant human interferon-gamma. Science (1991) 252:698–702. doi:10.1126/science.1902591
21. Takaoka A, Mitani Y, Suemori H, Sato M, Yokochi T, Noguchi S, et al. Cross talk between interferon-gamma and -alpha/beta signaling components in caveolar membrane domains. Science (2000) 288:2357–60. doi:10.1126/science.288.5475.2357
22. Mitani Y, Takaoka A, Kim SH, Kato Y, Yokochi T, Tanaka N, et al. Cross talk of the interferon-alpha/beta signalling complex with gp130 for effective interleukin-6 signalling. Genes Cells (2001) 6:631–40. doi:10.1046/j.1365-2443.2001.00448.x
23. Kasahara T, Hooks JJ, Dougherty SF, Oppenheim JJ. Interleukin 2-mediated immune interferon (IFN-gamma) production by human T cells and T cell subsets. J Immunol (1983) 130:1784–9.
24. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol (1986) 136:2348–57.
25. Corthay A, Skovseth DK, Lundin KU, Rosjo E, Omholt H, Hofgaard PO, et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity (2005) 22:371–83. doi:10.1016/j.immuni.2005.02.003
26. Matsushita H, Hosoi A, Ueha S, Abe J, Fujieda N, Tomura M, et al. Cytotoxic T lymphocytes block tumor growth both by lytic activity and IFNgamma-dependent cell-cycle arrest. Cancer Immunol Res (2015) 3:26–36. doi:10.1158/2326-6066.CIR-14-0098
27. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, et al. Regulation of cutaneous malignancy by gammadelta T cells. Science (2001) 294:605–9. doi:10.1126/science.1063916
28. Gao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH, et al. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med (2003) 198:433–42. doi:10.1084/jem.20030584
29. Girardi M, Glusac E, Filler RB, Roberts SJ, Propperova I, Lewis J, et al. The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer. J Exp Med (2003) 198:747–55. doi:10.1084/jem.20021282
30. Ribot JC, deBarros A, Pang DJ, Neves JF, Peperzak V, Roberts SJ, et al. CD27 is a thymic determinant of the balance between interferon-gamma- and interleukin 17-producing gammadelta T cell subsets. Nat Immunol (2009) 10:427–36. doi:10.1038/ni.1717
31. Lanca T, Costa MF, Goncalves-Sousa N, Rei M, Grosso AR, Penido C, et al. Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic gammadelta T lymphocytes to tumor beds. J Immunol (2013) 190:6673–80. doi:10.4049/jimmunol.1300434
32. Schmolka N, Serre K, Grosso AR, Rei M, Pennington DJ, Gomes AQ, et al. Epigenetic and transcriptional signatures of stable versus plastic differentiation of proinflammatory gammadelta T cell subsets. Nat Immunol (2013) 14:1093–100. doi:10.1038/ni.2702
33. Silva-Santos B, Serre K, Norell H. gammadelta T cells in cancer. Nat Rev Immunol (2015) 15:683–91. doi:10.1038/nri3904
34. Yu J, Wei M, Becknell B, Trotta R, Liu S, Boyd Z, et al. Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity (2006) 24:575–90. doi:10.1016/j.immuni.2006.03.016
35. Keppel MP, Saucier N, Mah AY, Vogel TP, Cooper MA. Activation-specific metabolic requirements for NK cell IFN-gamma production. J Immunol (2015) 194:1954–62. doi:10.4049/jimmunol.1402099
36. Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S, Okamura H, et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol (1998) 161:3400–7.
37. Flaishon L, Hershkoviz R, Lantner F, Lider O, Alon R, Levo Y, et al. Autocrine secretion of interferon gamma negatively regulates homing of immature B cells. J Exp Med (2000) 192:1381–8. doi:10.1084/jem.192.9.1381
38. Barr TA, Brown S, Mastroeni P, Gray D. TLR and B cell receptor signals to B cells differentially program primary and memory Th1 responses to Salmonella enterica. J Immunol (2010) 185:2783–9. doi:10.4049/jimmunol.1001431
39. Bao Y, Liu X, Han C, Xu S, Xie B, Zhang Q, et al. Identification of IFN-gamma-producing innate B cells. Cell Res (2014) 24:161–76. doi:10.1038/cr.2013.155
40. Ohteki T, Fukao T, Suzue K, Maki C, Ito M, Nakamura M, et al. Interleukin 12-dependent interferon gamma production by CD8alpha+ lymphoid dendritic cells. J Exp Med (1999) 189:1981–6. doi:10.1084/jem.189.12.1981
41. Zaidi MR, Davis S, Noonan FP, Graff-Cherry C, Hawley TS, Walker RL, et al. Interferon-gamma links ultraviolet radiation to melanomagenesis in mice. Nature (2011) 469:548–53. doi:10.1038/nature09666
42. Darwich L, Coma G, Pena R, Bellido R, Blanco EJ, Este JA, et al. Secretion of interferon-gamma by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18. Immunology (2009) 126:386–93. doi:10.1111/j.1365-2567.2008.02905.x
43. Chan SH, Perussia B, Gupta JW, Kobayashi M, Pospisil M, Young HA, et al. Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med (1991) 173:869–79. doi:10.1084/jem.173.4.869
44. Ye J, Ortaldo JR, Conlon K, Winkler-Pickett R, Young HA. Cellular and molecular mechanisms of IFN-gamma production induced by IL-2 and IL-12 in a human NK cell line. J Leukoc Biol (1995) 58:225–33. doi:10.1002/jlb.58.2.225
45. Carson WE, Ross ME, Baiocchi RA, Marien MJ, Boiani N, Grabstein K, et al. Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro. J Clin Invest (1995) 96:2578–82. doi:10.1172/JCI118321
46. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature (1995) 378:88–91. doi:10.1038/378088a0
47. Takeda K, Tsutsui H, Yoshimoto T, Adachi O, Yoshida N, Kishimoto T, et al. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity (1998) 8:383–90. doi:10.1016/S1074-7613(00)80543-9
48. Nguyen KB, Cousens LP, Doughty LA, Pien GC, Durbin JE, Biron CA. Interferon alpha/beta-mediated inhibition and promotion of interferon gamma: STAT1 resolves a paradox. Nat Immunol (2000) 1:70–6. doi:10.1038/76940
49. Matikainen S, Paananen A, Miettinen M, Kurimoto M, Timonen T, Julkunen I, et al. IFN-alpha and IL-18 synergistically enhance IFN-gamma production in human NK cells: differential regulation of Stat4 activation and IFN-gamma gene expression by IFN-alpha and IL-12. Eur J Immunol (2001) 31:2236–45. doi:10.1002/1521-4141(200107)31:7<2236::AID-IMMU2236>3.0.CO;2-G
50. de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM, et al. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol (2001) 69:912–20. doi:10.1189/jlb.69.6.912
51. Munder M, Mallo M, Eichmann K, Modolell M. Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J Exp Med (1998) 187:2103–8. doi:10.1084/jem.187.12.2103
52. Rothfuchs AG, Gigliotti D, Palmblad K, Andersson U, Wigzell H, Rottenberg ME. IFN-alpha beta-dependent, IFN-gamma secretion by bone marrow-derived macrophages controls an intracellular bacterial infection. J Immunol (2001) 167:6453–61. doi:10.4049/jimmunol.167.11.6453
53. Fricke I, Mitchell D, Mittelstadt J, Lehan N, Heine H, Goldmann T, et al. Mycobacteria induce IFN-gamma production in human dendritic cells via triggering of TLR2. J Immunol (2006) 176:5173–82. doi:10.4049/jimmunol.176.9.5173
54. Tovey MG, Streuli M, Gresser I, Gugenheim J, Blanchard B, Guymarho J, et al. Interferon messenger RNA is produced constitutively in the organs of normal individuals. Proc Natl Acad Sci U S A (1987) 84:5038–42. doi:10.1073/pnas.84.14.5038
55. Chen HM, Tanaka N, Mitani Y, Oda E, Nozawa H, Chen JZ, et al. Critical role for constitutive type I interferon signaling in the prevention of cellular transformation. Cancer Sci (2009) 100:449–56. doi:10.1111/j.1349-7006.2008.01051.x
56. Gattass CR, King LB, Luster AD, Ashwell JD. Constitutive expression of interferon gamma-inducible protein 10 in lymphoid organs and inducible expression in T cells and thymocytes. J Exp Med (1994) 179:1373–8. doi:10.1084/jem.179.4.1373
57. Sercan O, Hammerling GJ, Arnold B, Schuler T. Innate immune cells contribute to the IFN-gamma-dependent regulation of antigen-specific CD8+ T cell homeostasis. J Immunol (2006) 176:735–9. doi:10.4049/jimmunol.176.2.735
58. Baldridge MT, King KY, Boles NC, Weksberg DC, Goodell MA. Quiescent haematopoietic stem cells are activated by IFN-gamma in response to chronic infection. Nature (2010) 465:793–7. doi:10.1038/nature09135
59. Duque G, Huang DC, Dion N, Macoritto M, Rivas D, Li W, et al. Interferon-gamma plays a role in bone formation in vivo and rescues osteoporosis in ovariectomized mice. J Bone Miner Res (2011) 26:1472–83. doi:10.1002/jbmr.350
60. Karupiah G, Xie QW, Buller RM, Nathan C, Duarte C, MacMicking JD. Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science (1993) 261:1445–8. doi:10.1126/science.7690156
61. Shrestha B, Wang T, Samuel MA, Whitby K, Craft J, Fikrig E, et al. Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J Virol (2006) 80:5338–48. doi:10.1128/JVI.00274-06
62. Ferber IA, Brocke S, Taylor-Edwards C, Ridgway W, Dinisco C, Steinman L, et al. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol (1996) 156:5–7.
63. Sosa RA, Murphey C, Robinson RR, Forsthuber TG. IFN-gamma ameliorates autoimmune encephalomyelitis by limiting myelin lipid peroxidation. Proc Natl Acad Sci U S A (2015) 112:E5038–47. doi:10.1073/pnas.1505955112
64. Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI, Park YM, et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett (2006) 580:755–62. doi:10.1016/j.febslet.2005.12.093
65. Nakajima C, Uekusa Y, Iwasaki M, Yamaguchi N, Mukai T, Gao P, et al. A role of interferon-gamma (IFN-gamma) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-gamma-deficient mice. Cancer Res (2001) 61:3399–405.
66. Bernabei P, Coccia EM, Rigamonti L, Bosticardo M, Forni G, Pestka S, et al. Interferon-gamma receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death. J Leukoc Biol (2001) 70:950–60. doi:10.1189/jlb.70.6.950
67. Pernis A, Gupta S, Gollob KJ, Garfein E, Coffman RL, Schindler C, et al. Lack of interferon gamma receptor beta chain and the prevention of interferon gamma signaling in TH1 cells. Science (1995) 269:245–7. doi:10.1126/science.7618088
68. Bach EA, Szabo SJ, Dighe AS, Ashkenazi A, Aguet M, Murphy KM, et al. Ligand-induced autoregulation of IFN-gamma receptor beta chain expression in T helper cell subsets. Science (1995) 270:1215–8. doi:10.1126/science.270.5239.1215
69. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell (2000) 100:655–69. doi:10.1016/S0092-8674(00)80702-3
70. Bradley LM, Dalton DK, Croft M. A direct role for IFN-gamma in regulation of Th1 cell development. J Immunol (1996) 157:1350–8.
71. Girdlestone J, Wing M. Autocrine activation by interferon-gamma of STAT factors following T cell activation. Eur J Immunol (1996) 26:704–9. doi:10.1002/eji.1830260329
72. Lighvani AA, Frucht DM, Jankovic D, Yamane H, Aliberti J, Hissong BD, et al. T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc Natl Acad Sci U S A (2001) 98:15137–42. doi:10.1073/pnas.261570598
73. Maggi E, Parronchi P, Manetti R, Simonelli C, Piccinni MP, Rugiu FS, et al. Reciprocal regulatory effects of IFN-gamma and IL-4 on the in vitro development of human Th1 and Th2 clones. J Immunol (1992) 148:2142–7.
74. Halonen SK, Woods T, McInnerney K, Weiss LM. Microarray analysis of IFN-gamma response genes in astrocytes. J Neuroimmunol (2006) 175:19–30. doi:10.1016/j.jneuroim.2006.02.015
75. Rock RB, Hu S, Deshpande A, Munir S, May BJ, Baker CA, et al. Transcriptional response of human microglial cells to interferon-gamma. Genes Immun (2005) 6:712–9. doi:10.1038/sj.gene.6364246
76. Majoros A, Platanitis E, Kernbauer-Holzl E, Rosebrock F, Muller M, Decker T. Canonical and non-canonical aspects of JAK-STAT signaling: lessons from interferons for cytokine responses. Front Immunol (2017) 8:29. doi:10.3389/fimmu.2017.00029
77. Greenlund AC, Farrar MA, Viviano BL, Schreiber RD. Ligand-induced IFN gamma receptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91). EMBO J (1994) 13:1591–600.
78. Decker T, Lew DJ, Mirkovitch J, Darnell JE Jr. Cytoplasmic activation of GAF, an IFN-gamma-regulated DNA-binding factor. EMBO J (1991) 10:927–32.
79. Chatterjee-Kishore M, Wright KL, Ting JP, Stark GR. How Stat1 mediates constitutive gene expression: a complex of unphosphorylated Stat1 and IRF1 supports transcription of the LMP2 gene. EMBO J (2000) 19:4111–22. doi:10.1093/emboj/19.15.4111
80. Rettino A, Clarke NM. Genome-wide identification of IRF1 binding sites reveals extensive occupancy at cell death associated genes. J Carcinog Mutagen (2013) S6-009:2157–518. doi:10.4172/2157-2518.S6-009
81. Murtas D, Maric D, De Giorgi V, Reinboth J, Worschech A, Fetsch P, et al. IRF-1 responsiveness to IFN-gamma predicts different cancer immune phenotypes. Br J Cancer (2013) 109:76–82. doi:10.1038/bjc.2013.335
82. Ulloa L, Doody J, Massague J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature (1999) 397:710–3. doi:10.1038/17826
83. Ramana CV, Grammatikakis N, Chernov M, Nguyen H, Goh KC, Williams BR, et al. Regulation of c-myc expression by IFN-gamma through Stat1-dependent and -independent pathways. EMBO J (2000) 19:263–72. doi:10.1093/emboj/19.2.263
84. Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science (1996) 272:719–22. doi:10.1126/science.272.5262.719
85. Xing S, Wanting TH, Zhao W, Ma J, Wang S, Xu X, et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood (2008) 111:5109–17. doi:10.1182/blood-2007-05-091579
86. Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med (2008) 205:751–8. doi:10.1084/jem.20072182
87. Bottos A, Gotthardt D, Gill JW, Gattelli A, Frei A, Tzankov A, et al. Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models. Nat Commun (2016) 7:12258. doi:10.1038/ncomms12258
88. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 9:798–809. doi:10.1038/nrc2734
89. Messina NL, Banks KM, Vidacs E, Martin BP, Long F, Christiansen AJ, et al. Modulation of antitumour immune responses by intratumoural Stat1 expression. Immunol Cell Biol (2013) 91:556–67. doi:10.1038/icb.2013.41
90. Fallarino F, Gajewski TF. Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J Immunol (1999) 163:4109–13.
91. Chan SR, Vermi W, Luo J, Lucini L, Rickert C, Fowler AM, et al. STAT1-deficient mice spontaneously develop estrogen receptor alpha-positive luminal mammary carcinomas. Breast Cancer Res (2012) 14:R16. doi:10.1186/bcr3100
92. Andrianifahanana M, Singh AP, Nemos C, Ponnusamy MP, Moniaux N, Mehta PP, et al. IFN-gamma-induced expression of MUC4 in pancreatic cancer cells is mediated by STAT-1 upregulation: a novel mechanism for IFN-gamma response. Oncogene (2007) 26:7251–61. doi:10.1038/sj.onc.1210532
93. Hix LM, Karavitis J, Khan MW, Shi YH, Khazaie K, Zhang M. Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells. J Biol Chem (2013) 288:11676–88. doi:10.1074/jbc.M112.441402
94. Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, Khodarev N, et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A (2008) 105:18490–5. doi:10.1073/pnas.0809242105
95. Khodarev NN, Roach P, Pitroda SP, Golden DW, Bhayani M, Shao MY, et al. STAT1 pathway mediates amplification of metastatic potential and resistance to therapy. PLoS One (2009) 4:e5821. doi:10.1371/journal.pone.0005821
96. Jauch D, Martin M, Schiechl G, Kesselring R, Schlitt HJ, Geissler EK, et al. Interleukin 21 controls tumour growth and tumour immunosurveillance in colitis-associated tumorigenesis in mice. Gut (2011) 60:1678–86. doi:10.1136/gutjnl-2011-300612
97. Carbotti G, Barisione G, Airoldi I, Mezzanzanica D, Bagnoli M, Ferrero S, et al. IL-27 induces the expression of IDO and PD-L1 in human cancer cells. Oncotarget (2015) 6:43267–80. doi:10.18632/oncotarget.6530
98. Turnis ME, Sawant DV, Szymczak-Workman AL, Andrews LP, Delgoffe GM, Yano H, et al. Interleukin-35 limits anti-tumor immunity. Immunity (2016) 44:316–29. doi:10.1016/j.immuni.2016.01.013
99. Huang C, Li N, Li Z, Chang A, Chen Y, Zhao T, et al. Tumour-derived Interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression. Nat Commun (2017) 8:14035. doi:10.1038/ncomms14035
100. Zhao Z, Chen X, Hao S, Jia R, Wang N, Chen S, et al. Increased interleukin-35 expression in tumor-infiltrating lymphocytes correlates with poor prognosis in patients with breast cancer. Cytokine (2017) 89:76–81. doi:10.1016/j.cyto.2016.09.012
101. Zou JM, Qin J, Li YC, Wang Y, Li D, Shu Y, et al. IL-35 induces N2 phenotype of neutrophils to promote tumor growth. Oncotarget (2017) 8:33501–14. doi:10.18632/oncotarget.16819
102. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature (1997) 387:921–4. doi:10.1038/43213
103. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signalling. Nature (1997) 387:917–21. doi:10.1038/43206
104. Zhang JG, Farley A, Nicholson SE, Willson TA, Zugaro LM, Simpson RJ, et al. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci U S A (1999) 96:2071–6. doi:10.1073/pnas.96.5.2071
105. Kamizono S, Hanada T, Yasukawa H, Minoguchi S, Kato R, Minoguchi M, et al. The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. J Biol Chem (2001) 276:12530–8. doi:10.1074/jbc.M010074200
106. Chang JH, Xiao Y, Hu H, Jin J, Yu J, Zhou X, et al. Ubc13 maintains the suppressive function of regulatory T cells and prevents their conversion into effector-like T cells. Nat Immunol (2012) 13:481–90. doi:10.1038/ni.2267
107. Kim WS, Kim MJ, Kim DO, Byun JE, Huy H, Song HY, et al. Suppressor of cytokine signaling 2 negatively regulates NK cell differentiation by inhibiting JAK2 activity. Sci Rep (2017) 7:46153. doi:10.1038/srep46153
108. Choudhury GG. A linear signal transduction pathway involving phosphatidylinositol 3-kinase, protein kinase Cepsilon, and MAPK in mesangial cells regulates interferon-gamma-induced STAT1alpha transcriptional activation. J Biol Chem (2004) 279:27399–409. doi:10.1074/jbc.M403530200
109. Qing Y, Stark GR. Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J Biol Chem (2004) 279:41679–85. doi:10.1074/jbc.M406413200
110. Meinke A, Barahmand-Pour F, Wohrl S, Stoiber D, Decker T. Activation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferons. Mol Cell Biol (1996) 16:6937–44. doi:10.1128/MCB.16.12.6937
111. Deb A, Haque SJ, Mogensen T, Silverman RH, Williams BR. RNA-dependent protein kinase PKR is required for activation of NF-kappa B by IFN-gamma in a STAT1-independent pathway. J Immunol (2001) 166:6170–80. doi:10.4049/jimmunol.166.10.6170
112. Lewis M, Amento EP, Unemori EN. Transcriptional inhibition of stromelysin by interferon-gamma in normal human fibroblasts is mediated by the AP-1 domain. J Cell Biochem (1999) 72:373–86. doi:10.1002/(SICI)1097-4644(19990301)72:3<373::AID-JCB7>3.0.CO;2-N
113. Shirayoshi Y, Burke PA, Appella E, Ozato K. Interferon-induced transcription of a major histocompatibility class I gene accompanies binding of inducible nuclear factors to the interferon consensus sequence. Proc Natl Acad Sci U S A (1988) 85:5884–8. doi:10.1073/pnas.85.16.5884
114. Amaldi I, Reith W, Berte C, Mach B. Induction of HLA class II genes by IFN-gamma is transcriptional and requires a trans-acting protein. J Immunol (1989) 142:999–1004.
115. Belich MP, Glynne RJ, Senger G, Sheer D, Trowsdale J. Proteasome components with reciprocal expression to that of the MHC-encoded LMP proteins. Curr Biol (1994) 4:769–76. doi:10.1016/S0960-9822(00)00174-3
116. Nandi D, Jiang H, Monaco JJ. Identification of MECL-1 (LMP-10) as the third IFN-gamma-inducible proteasome subunit. J Immunol (1996) 156:2361–4.
117. Cramer LA, Nelson SL, Klemsz MJ. Synergistic induction of the Tap-1 gene by IFN-gamma and lipopolysaccharide in macrophages is regulated by STAT1. J Immunol (2000) 165:3190–7. doi:10.4049/jimmunol.165.6.3190
118. Johnson DR, Pober JS. Tumor necrosis factor and immune interferon synergistically increase transcription of HLA class I heavy- and light-chain genes in vascular endothelium. Proc Natl Acad Sci U S A (1990) 87:5183–7. doi:10.1073/pnas.87.13.5183
119. Seliger B, Schreiber K, Delp K, Meissner M, Hammers S, Reichert T, et al. Downregulation of the constitutive tapasin expression in human tumor cells of distinct origin and its transcriptional upregulation by cytokines. Tissue Antigens (2001) 57:39–45. doi:10.1034/j.1399-0039.2001.057001039.x
120. Kern I, Steimle V, Siegrist CA, Mach B. The two novel MHC class II transactivators RFX5 and CIITA both control expression of HLA-DM genes. Int Immunol (1995) 7:1295–9. doi:10.1093/intimm/7.8.1295
121. Lah TT, Hawley M, Rock KL, Goldberg AL. Gamma-interferon causes a selective induction of the lysosomal proteases, cathepsins B and L, in macrophages. FEBS Lett (1995) 363:85–9. doi:10.1016/0014-5793(95)00287-J
122. Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science (1994) 265:106–9. doi:10.1126/science.8016643
123. Zhao M, Flynt FL, Hong M, Chen H, Gilbert CA, Briley NT, et al. MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-gamma. Mol Immunol (2007) 44:2923–32. doi:10.1016/j.molimm.2007.01.009
124. Deffrennes V, Vedrenne J, Stolzenberg MC, Piskurich J, Barbieri G, Ting JP, et al. Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter. J Immunol (2001) 167:98–106. doi:10.4049/jimmunol.167.1.98
125. Maraskovsky E, Chen WF, Shortman K. IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells. J Immunol (1989) 143:1210–4.
126. Curtsinger JM, Agarwal P, Lins DC, Mescher MF. Autocrine IFN-gamma promotes naive CD8 T cell differentiation and synergizes with IFN-alpha to stimulate strong function. J Immunol (2012) 189:659–68. doi:10.4049/jimmunol.1102727
127. Akbar SM, Inaba K, Onji M. Upregulation of MHC class II antigen on dendritic cells from hepatitis B virus transgenic mice by interferon-gamma: abrogation of immune response defect to a T-cell-dependent antigen. Immunology (1996) 87:519–27. doi:10.1046/j.1365-2567.1996.516576.x
128. Walter W, Lingnau K, Schmitt E, Loos M, Maeurer MJ. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? Br J Cancer (2000) 83:1192–201. doi:10.1054/bjoc.2000.1415
129. Haabeth OA, Lorvik KB, Hammarstrom C, Donaldson IM, Haraldsen G, Bogen B, et al. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun (2011) 2:240. doi:10.1038/ncomms1239
130. Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med (1983) 158:670–89. doi:10.1084/jem.158.3.670
131. Sadlik JR, Hoyer M, Leyko MA, Horvat R, Parmely M, Whitacre C, et al. Lymphocyte supernatant-induced human monocyte tumoricidal activity: dependence on the presence of gamma-interferon. Cancer Res (1985) 45:1940–5.
132. Taniyama T, Taki S, Akiyama Y, Yoshizawa K, Hamuro J, Arai K, et al. Constitutive production of novel macrophage-activating factor(s) by human T cell hybridomas. Clin Invest Med (1990) 13:305–12.
133. Higuchi M, Sugimoto M, Kobayashi Y, Osawa T. Human macrophage-activating factors for cytotoxicity. I. Establishment of a human T-cell hybridoma that produces macrophage-activating factors for cytotoxicity. Microbiol Immunol (1987) 31:469–79. doi:10.1111/j.1348-0421.1987.tb03109.x
134. Waddell SJ, Popper SJ, Rubins KH, Griffiths MJ, Brown PO, Levin M, et al. Dissecting interferon-induced transcriptional programs in human peripheral blood cells. PLoS One (2010) 5:e9753. doi:10.1371/journal.pone.0009753
135. Shiloh MU, MacMicking JD, Nicholson S, Brause JE, Potter S, Marino M, et al. Phenotype of mice and macrophages deficient in both phagocyte oxidase and inducible nitric oxide synthase. Immunity (1999) 10:29–38. doi:10.1016/S1074-7613(00)80004-7
136. Pfefferkorn ER. Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci U S A (1984) 81:908–12. doi:10.1073/pnas.81.3.908
137. Pak-Wittel MA, Yang L, Sojka DK, Rivenbark JG, Yokoyama WM. Interferon-gamma mediates chemokine-dependent recruitment of natural killer cells during viral infection. Proc Natl Acad Sci U S A (2013) 110:E50–9. doi:10.1073/pnas.1220456110
138. Valledor AF, Sanchez-Tillo E, Arpa L, Park JM, Caelles C, Lloberas J, et al. Selective roles of MAPKs during the macrophage response to IFN-gamma. J Immunol (2008) 180:4523–9. doi:10.4049/jimmunol.180.7.4523
139. Zhang Y, Apilado R, Coleman J, Ben-Sasson S, Tsang S, Hu-Li J, et al. Interferon gamma stabilizes the T helper cell type 1 phenotype. J Exp Med (2001) 194:165–72. doi:10.1084/jem.194.2.165
140. Maldonado RA, Irvine DJ, Schreiber R, Glimcher LH. A role for the immunological synapse in lineage commitment of CD4 lymphocytes. Nature (2004) 431:527–32. doi:10.1038/nature02916
141. Schulz EG, Mariani L, Radbruch A, Hofer T. Sequential polarization and imprinting of type 1 T helper lymphocytes by interferon-gamma and interleukin-12. Immunity (2009) 30:673–83. doi:10.1016/j.immuni.2009.03.013
142. Oriss TB, McCarthy SA, Morel BF, Campana MA, Morel PA. Crossregulation between T helper cell (Th)1 and Th2: inhibition of Th2 proliferation by IFN-gamma involves interference with IL-1. J Immunol (1997) 158:3666–72.
143. Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol (1988) 140:4245–52.
144. Naka T, Tsutsui H, Fujimoto M, Kawazoe Y, Kohzaki H, Morita Y, et al. SOCS-1/SSI-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFN-gamma and IL-4 signaling in vivo. Immunity (2001) 14:535–45. doi:10.1016/S1074-7613(01)00132-7
145. Yu CR, Mahdi RM, Ebong S, Vistica BP, Chen J, Guo Y, et al. Cell proliferation and STAT6 pathways are negatively regulated in T cells by STAT1 and suppressors of cytokine signaling. J Immunol (2004) 173:737–46. doi:10.4049/jimmunol.173.2.737
146. Hwang ES, Szabo SJ, Schwartzberg PL, Glimcher LH. T helper cell fate specified by kinase-mediated interaction of T-bet with GATA-3. Science (2005) 307:430–3. doi:10.1126/science.1103336
147. Höfer T, Nathansen H, Lohning M, Radbruch A, Heinrich R. GATA-3 transcriptional imprinting in Th2 lymphocytes: a mathematical model. Proc Natl Acad Sci U S A (2002) 99:9364–8. doi:10.1073/pnas.142284699
148. Kurata H, Lee HJ, O’Garra A, Arai N. Ectopic expression of activated Stat6 induces the expression of Th2-specific cytokines and transcription factors in developing Th1 cells. Immunity (1999) 11:677–88. doi:10.1016/S1074-7613(00)80142-9
149. Ouyang W, Lohning M, Gao Z, Assenmacher M, Ranganath S, Radbruch A, et al. Stat6-independent GATA-3 autoactivation directs IL-4-independent Th2 development and commitment. Immunity (2000) 12:27–37. doi:10.1016/S1074-7613(00)80156-9
150. Dickensheets HL, Donnelly RP. Inhibition of IL-4-inducible gene expression in human monocytes by type I and type II interferons. J Leukoc Biol (1999) 65:307–12. doi:10.1002/jlb.65.3.307
151. Kacha AK, Fallarino F, Markiewicz MA, Gajewski TF. Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J Immunol (2000) 165:6024–8. doi:10.4049/jimmunol.165.11.6024
152. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol (2005) 6:1123–32. doi:10.1038/ni1254
153. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol (2005) 6:1133–41. doi:10.1038/ni1261
154. Kelchtermans H, Schurgers E, Geboes L, Mitera T, Van Damme J, Van Snick J, et al. Effector mechanisms of interleukin-17 in collagen-induced arthritis in the absence of interferon-gamma and counteraction by interferon-gamma. Arthritis Res Ther (2009) 11:R122. doi:10.1186/ar2787
155. Kimura A, Naka T, Nohara K, Fujii-Kuriyama Y, Kishimoto T. Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci U S A (2008) 105:9721–6. doi:10.1073/pnas.0804231105
156. Tanaka K, Ichiyama K, Hashimoto M, Yoshida H, Takimoto T, Takaesu G, et al. Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads. J Immunol (2008) 180:3746–56. doi:10.4049/jimmunol.180.6.3746
157. Herrero C, Hu X, Li WP, Samuels S, Sharif MN, Kotenko S, et al. Reprogramming of IL-10 activity and signaling by IFN-gamma. J Immunol (2003) 171:5034–41. doi:10.4049/jimmunol.171.10.5034
158. Lazarevic V, Chen X, Shim JH, Hwang ES, Jang E, Bolm AN, et al. T-bet represses T(H)17 differentiation by preventing Runx1-mediated activation of the gene encoding RORgammat. Nat Immunol (2011) 12:96–104. doi:10.1038/ni.1969
159. Barrios-Rodiles M, Chadee K. Novel regulation of cyclooxygenase-2 expression and prostaglandin E2 production by IFN-gamma in human macrophages. J Immunol (1998) 161:2441–8.
160. Zhou M, Zhang Y, Ardans JA, Wahl LM. Interferon-gamma differentially regulates monocyte matrix metalloproteinase-1 and -9 through tumor necrosis factor-alpha and caspase 8. J Biol Chem (2003) 278:45406–13. doi:10.1074/jbc.M309075200
161. Irmler IM, Gajda M, Brauer R. Exacerbation of antigen-induced arthritis in IFN-gamma-deficient mice as a result of unrestricted IL-17 response. J Immunol (2007) 179:6228–36. doi:10.4049/jimmunol.179.9.6228
162. Kelchtermans H, Struyf S, De Klerck B, Mitera T, Alen M, Geboes L, et al. Protective role of IFN-gamma in collagen-induced arthritis conferred by inhibition of mycobacteria-induced granulocyte chemotactic protein-2 production. J Leukoc Biol (2007) 81:1044–53. doi:10.1189/jlb.0806486
163. Hu X, Paik PK, Chen J, Yarilina A, Kockeritz L, Lu TT, et al. IFN-gamma suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins. Immunity (2006) 24:563–74. doi:10.1016/j.immuni.2006.02.014
164. Park IK, Letterio JJ, Gorham JD. TGF-beta 1 inhibition of IFN-gamma-induced signaling and Th1 gene expression in CD4+ T cells is Smad3 independent but MAP kinase dependent. Mol Immunol (2007) 44:3283–90. doi:10.1016/j.molimm.2007.02.024
165. Caretto D, Katzman SD, Villarino AV, Gallo E, Abbas AK. Cutting edge: the Th1 response inhibits the generation of peripheral regulatory T cells. J Immunol (2010) 184:30–4. doi:10.4049/jimmunol.0903412
166. Olalekan SA, Cao Y, Hamel KM, Finnegan A. B cells expressing IFN-gamma suppress Treg-cell differentiation and promote autoimmune experimental arthritis. Eur J Immunol (2015) 45:988–98. doi:10.1002/eji.201445036
167. Willenborg DO, Fordham S, Bernard CC, Cowden WB, Ramshaw IA. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol (1996) 157:3223–7.
168. Nishibori T, Tanabe Y, Su L, David M. Impaired development of CD4+ CD25+ regulatory T cells in the absence of STAT1: increased susceptibility to autoimmune disease. J Exp Med (2004) 199:25–34. doi:10.1084/jem.20020509
169. Wang Z, Hong J, Sun W, Xu G, Li N, Chen X, et al. Role of IFN-gamma in induction of Foxp3 and conversion of CD4+ CD25- T cells to CD4+ Tregs. J Clin Invest (2006) 116:2434–41. doi:10.1172/JCI25826
170. Vermeire K, Heremans H, Vandeputte M, Huang S, Billiau A, Matthys P. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol (1997) 158:5507–13.
171. Wei B, Baker S, Wieckiewicz J, Wood KJ. IFN-gamma triggered STAT1-PKB/AKT signalling pathway influences the function of alloantigen reactive regulatory T cells. Am J Transplant (2010) 10:69–80. doi:10.1111/j.1600-6143.2009.02858.x
172. Feng T, Cao AT, Weaver CT, Elson CO, Cong Y. Interleukin-12 converts Foxp3+ regulatory T cells to interferon-gamma-producing Foxp3+ T cells that inhibit colitis. Gastroenterology (2011) 140:2031–43. doi:10.1053/j.gastro.2011.03.009
173. Sawitzki B, Kingsley CI, Oliveira V, Karim M, Herber M, Wood KJ. IFN-gamma production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo. J Exp Med (2005) 201:1925–35. doi:10.1084/jem.20050419
174. Koenecke C, Lee CW, Thamm K, Fohse L, Schafferus M, Mittrucker HW, et al. IFN-gamma production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease. J Immunol (2012) 189:2890–6. doi:10.4049/jimmunol.1200413
175. Greifenberg V, Ribechini E, Rossner S, Lutz MB. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur J Immunol (2009) 39:2865–76. doi:10.1002/eji.200939486
176. Shime H, Maruyama A, Yoshida S, Takeda Y, Matsumoto M, Seya T. Toll-like receptor 2 ligand and interferon-gamma suppress anti-tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells. Oncoimmunology (2017) 7:e1373231. doi:10.1080/2162402X.2017.1373231
177. Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J (1991) 5:2516–22. doi:10.1096/fasebj.5.11.1907934
178. Malone DG, Dolan PW, Brown RR, Kalayoglu MV, Arend RA, Byrne GI, et al. Interferon gamma induced production of indoleamine 2,3 dioxygenase in cultured human synovial cells. J Rheumatol (1994) 21:1011–9.
179. Jurgens B, Hainz U, Fuchs D, Felzmann T, Heitger A. Interferon-gamma-triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells. Blood (2009) 114:3235–43. doi:10.1182/blood-2008-12-195073
180. Sarkar SA, Wong R, Hackl SI, Moua O, Gill RG, Wiseman A, et al. Induction of indoleamine 2,3-dioxygenase by interferon-gamma in human islets. Diabetes (2007) 56:72–9. doi:10.2337/db06-0617
181. Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, et al. IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer (2015) 112:1501–9. doi:10.1038/bjc.2015.101
182. Mimura K, Teh JL, Okayama H, Shiraishi K, Kua LF, Koh V, et al. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci (2018) 109:43–53. doi:10.1111/cas.13424
183. Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep (2017) 19:1189–201. doi:10.1016/j.celrep.2017.04.031
184. Beatty G, Paterson Y. IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. J Immunol (2001) 166:2276–82. doi:10.4049/jimmunol.166.4.2276
185. Zhang R, Banik NL, Ray SK. Combination of all-trans retinoic acid and interferon-gamma suppressed PI3K/Akt survival pathway in glioblastoma T98G cells whereas NF-kappaB survival signaling in glioblastoma U87MG cells for induction of apoptosis. Neurochem Res (2007) 32:2194–202. doi:10.1007/s11064-007-9417-7
186. Detjen KM, Farwig K, Welzel M, Wiedenmann B, Rosewicz S. Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis. Gut (2001) 49:251–62. doi:10.1136/gut.49.2.251
187. Kotredes KP, Gamero AM. Interferons as inducers of apoptosis in malignant cells. J Interferon Cytokine Res (2013) 33:162–70. doi:10.1089/jir.2012.0110
188. Sucker A, Zhao F, Pieper N, Heeke C, Maltaner R, Stadtler N, et al. Acquired IFNgamma resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. Nat Commun (2017) 8:15440. doi:10.1038/ncomms15440
189. Heyman M, Grander D, Brondum-Nielsen K, Cederblad B, Liu Y, Xu B, et al. Interferon system defects in malignant T-cells. Leukemia (1994) 8:425–34.
190. Satoh A, Toyota M, Ikeda H, Morimoto Y, Akino K, Mita H, et al. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells. Oncogene (2004) 23:8876–86. doi:10.1038/sj.onc.1208144
191. van den Elsen PJ, Holling TM, van der Stoep N, Boss JM. DNA methylation and expression of major histocompatibility complex class I and class II transactivator genes in human developmental tumor cells and in T cell malignancies. Clin Immunol (2003) 109:46–52. doi:10.1016/S1521-6616(03)00200-6
192. Yazawa T, Kamma H, Fujiwara M, Matsui M, Horiguchi H, Satoh H, et al. Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer. J Pathol (1999) 187:191–9. doi:10.1002/(SICI)1096-9896(199901)187:2<191::AID-PATH206>3.0.CO;2-3
193. van der Stoep N, Biesta P, Quinten E, van den Elsen PJ. Lack of IFN-gamma-mediated induction of the class II transactivator (CIITA) through promoter methylation is predominantly found in developmental tumor cell lines. Int J Cancer (2002) 97:501–7. doi:10.1002/ijc.1623
194. Croce M, De Ambrosis A, Corrias MV, Pistoia V, Occhino M, Meazza R, et al. Different levels of control prevent interferon-gamma-inducible HLA-class II expression in human neuroblastoma cells. Oncogene (2003) 22:7848–57. doi:10.1038/sj.onc.1207054
195. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol (2006) 6:836–48. doi:10.1038/nri1961
196. Dunn GP, Ikeda H, Bruce AT, Koebel C, Uppaluri R, Bui J, et al. Interferon-gamma and cancer immunoediting. Immunol Res (2005) 32:231–45. doi:10.1385/IR:32:1-3:231
197. Bromberg JF, Horvath CM, Wen Z, Schreiber RD, Darnell JE Jr. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci U S A (1996) 93:7673–8. doi:10.1073/pnas.93.15.7673
198. Fulda S, Debatin KM. IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene (2002) 21:2295–308. doi:10.1038/sj.onc.1205255
199. Chin YE, Kitagawa M, Kuida K, Flavell RA, Fu XY. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol (1997) 17:5328–37. doi:10.1128/MCB.17.9.5328
200. Xu X, Fu XY, Plate J, Chong AS. IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res (1998) 58:2832–7.
201. Liu F, Hu X, Zimmerman M, Waller JL, Wu P, Hayes-Jordan A, et al. TNFalpha cooperates with IFN-gamma to repress Bcl-xL expression to sensitize metastatic colon carcinoma cells to TRAIL-mediated apoptosis. PLoS One (2011) 6:e16241. doi:10.1371/journal.pone.0016241
202. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med (2002) 195:161–9. doi:10.1084/jem.20011171
203. Thapa RJ, Basagoudanavar SH, Nogusa S, Irrinki K, Mallilankaraman K, Slifker MJ, et al. NF-kappaB protects cells from gamma interferon-induced RIP1-dependent necroptosis. Mol Cell Biol (2011) 31:2934–46. doi:10.1128/MCB.05445-11
204. Hayakawa Y, Takeda K, Yagita H, Smyth MJ, Van Kaer L, Okumura K, et al. IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood (2002) 100:1728–33.
205. Kammertoens T, Friese C, Arina A, Idel C, Briesemeister D, Rothe M, et al. Tumour ischaemia by interferon-gamma resembles physiological blood vessel regression. Nature (2017) 545:98–102. doi:10.1038/nature22311
206. Briesemeister D, Sommermeyer D, Loddenkemper C, Loew R, Uckert W, Blankenstein T, et al. Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis. Int J Cancer (2011) 128:371–8. doi:10.1002/ijc.25350
207. Martini M, Testi MG, Pasetto M, Picchio MC, Innamorati G, Mazzocco M, et al. IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine (2010) 28:3548–57. doi:10.1016/j.vaccine.2010.03.007
208. Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol (2011) 89:207–15. doi:10.1038/icb.2010.158
209. Melero I, Rouzaut A, Motz GT, Coukos G. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov (2014) 4:522–6. doi:10.1158/2159-8290.CD-13-0985
210. Barreira da Silva R, Laird ME, Yatim N, Fiette L, Ingersoll MA, Albert ML. Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. Nat Immunol (2015) 16:850–8. doi:10.1038/ni.3201
211. Gordon-Alonso M, Hirsch T, Wildmann C, van der Bruggen P. Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration. Nat Commun (2017) 8:793. doi:10.1038/s41467-017-00925-6
212. Campanella GS, Colvin RA, Luster AD. CXCL10 can inhibit endothelial cell proliferation independently of CXCR3. PLoS One (2010) 5:e12700. doi:10.1371/journal.pone.0012700
213. Feldman ED, Weinreich DM, Carroll NM, Burness ML, Feldman AL, Turner E, et al. Interferon gamma-inducible protein 10 selectively inhibits proliferation and induces apoptosis in endothelial cells. Ann Surg Oncol (2006) 13:125–33. doi:10.1245/ASO.2006.03.038
214. Zhang T, Sun HC, Zhou HY, Luo JT, Zhang BL, Wang P, et al. Interferon alpha inhibits hepatocellular carcinoma growth through inducing apoptosis and interfering with adhesion of tumor endothelial cells. Cancer Lett (2010) 290:204–10. doi:10.1016/j.canlet.2009.09.009
215. Ligocki AJ, Brown JR, Niederkorn JY. Role of interferon-gamma and cytotoxic T lymphocytes in intraocular tumor rejection. J Leukoc Biol (2016) 99:735–47. doi:10.1189/jlb.3A0315-093RRR
216. Zimmerman M, Yang D, Hu X, Liu F, Singh N, Browning D, et al. IFN-gamma upregulates survivin and Ifi202 expression to induce survival and proliferation of tumor-specific T cells. PLoS One (2010) 5:e14076. doi:10.1371/journal.pone.0014076
217. Celada A, Gray PW, Rinderknecht E, Schreiber RD. Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity. J Exp Med (1984) 160:55–74. doi:10.1084/jem.160.1.55
218. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol (2005) 174:636–45. doi:10.4049/jimmunol.174.2.636
219. Zhang C, Hou D, Wei H, Zhao M, Yang L, Liu Q, et al. Lack of interferon-gamma receptor results in a microenvironment favorable for intestinal tumorigenesis. Oncotarget (2016) 7:42099–109. doi:10.18632/oncotarget.9867
220. Duluc D, Corvaisier M, Blanchard S, Catala L, Descamps P, Gamelin E, et al. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int J Cancer (2009) 125:367–73. doi:10.1002/ijc.24401
221. Cardoso AP, Goncalves RM, Antunes JC, Pinto ML, Pinto AT, Castro F, et al. An interferon-gamma-delivery system based on chitosan/poly(gamma-glutamic acid) polyelectrolyte complexes modulates macrophage-derived stimulation of cancer cell invasion in vitro. Acta Biomater (2015) 23:157–71. doi:10.1016/j.actbio.2015.05.022
222. Yu WG, Ogawa M, Mu J, Umehara K, Tsujimura T, Fujiwara H, et al. IL-12-induced tumor regression correlates with in situ activity of IFN-gamma produced by tumor-infiltrating cells and its secondary induction of anti-tumor pathways. J Leukoc Biol (1997) 62:450–7. doi:10.1002/jlb.62.4.450
223. Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, et al. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity (1998) 9:25–34. doi:10.1016/S1074-7613(00)80585-3
224. Abdi K, Singh N, Matzinger P. T-cell control of IL-12p75 production. Scand J Immunol (2006) 64:83–92. doi:10.1111/j.1365-3083.2006.01767.x
225. Snijders A, Kalinski P, Hilkens CM, Kapsenberg ML. High-level IL-12 production by human dendritic cells requires two signals. Int Immunol (1998) 10:1593–8. doi:10.1093/intimm/10.11.1593
226. Noguchi Y, Jungbluth A, Richards EC, Old LJ. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc Natl Acad Sci U S A (1996) 93:11798–801. doi:10.1073/pnas.93.21.11798
227. Komita H, Homma S, Saotome H, Zeniya M, Ohno T, Toda G. Interferon-gamma produced by interleukin-12-activated tumor infiltrating CD8+T cells directly induces apoptosis of mouse hepatocellular carcinoma. J Hepatol (2006) 45:662–72. doi:10.1016/j.jhep.2006.05.018
228. Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res (2011) 71:5697–706. doi:10.1158/0008-5472.CAN-11-0103
229. Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood (2012) 119:4133–41. doi:10.1182/blood-2011-12-400044
230. Zhang L, Kerkar SP, Yu Z, Zheng Z, Yang S, Restifo NP, et al. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther (2011) 19:751–9. doi:10.1038/mt.2010.313
231. Simpson JA, Al-Attar A, Watson NF, Scholefield JH, Ilyas M, Durrant LG. Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer. Gut (2010) 59:926–33. doi:10.1136/gut.2009.194472
232. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 12:298–306. doi:10.1038/nrc3245
233. Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest (2017) 127:2930–40. doi:10.1172/JCI91190
234. Karachaliou N, Gonzalez-Cao M, Crespo G, Drozdowskyj A, Aldeguer E, Gimenez-Capitan A, et al. Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Ther Adv Med Oncol (2018) 10:1758834017749748. doi:10.1177/1758834017749748
235. Mo X, Zhang H, Preston S, Martin K, Zhou B, Vadalia N, et al. Interferon-gamma signaling in melanocytes and melanoma cells regulates expression of CTLA-4. Cancer Res (2018) 78:436–50. doi:10.1158/0008-5472.CAN-17-1615
236. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 107:4275–80. doi:10.1073/pnas.0915174107
237. Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One (2011) 6:e19499. doi:10.1371/journal.pone.0019499
238. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A (2008) 105:14987–92. doi:10.1073/pnas.0806075105
239. Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res (2012) 72:5209–18. doi:10.1158/0008-5472.CAN-12-1187
240. Overacre-Delgoffe AE, Chikina M, Dadey RE, Yano H, Brunazzi EA, Shayan G, et al. Interferon-gamma drives Treg fragility to promote anti-tumor immunity. Cell (2017) 169:1130–41.e11. doi:10.1016/j.cell.2017.05.005
241. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, et al. Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell (2016) 167:397–404.e9. doi:10.1016/j.cell.2016.08.069
242. Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M, et al. Identification of essential genes for cancer immunotherapy. Nature (2017) 548:537–42. doi:10.1038/nature23477
243. Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, et al. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer (2000) 82:1138–44. doi:10.1054/bjoc.1999.1053
244. Giannopoulos A, Constantinides C, Fokaeas E, Stravodimos C, Giannopoulou M, Kyroudi A, et al. The immunomodulating effect of interferon-gamma intravesical instillations in preventing bladder cancer recurrence. Clin Cancer Res (2003) 9:5550–8.
245. Khammari A, Nguyen JM, Saint-Jean M, Knol AC, Pandolfino MC, Quereux G, et al. Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-gamma) in metastatic melanoma patients. Cancer Immunol Immunother (2015) 64:805–15. doi:10.1007/s00262-015-1691-7
246. Lesinski GB, Zimmerer JM, Kreiner M, Trefry J, Bill MA, Young GS, et al. Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells. BMC Cancer (2010) 10:142. doi:10.1186/1471-2407-10-142
247. Evans MK, Yu CR, Lohani A, Mahdi RM, Liu X, Trzeciak AR, et al. Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals. Oncogene (2007) 26:1941–8. doi:10.1038/sj.onc.1209993
248. Zaidi MR, Merlino G. The two faces of interferon-gamma in cancer. Clin Cancer Res (2011) 17:6118–24. doi:10.1158/1078-0432.CCR-11-0482
249. Taniguchi K, Petersson M, Hoglund P, Kiessling R, Klein G, Karre K. Interferon gamma induces lung colonization by intravenously inoculated B16 melanoma cells in parallel with enhanced expression of class I major histocompatibility complex antigens. Proc Natl Acad Sci U S A (1987) 84:3405–9. doi:10.1073/pnas.84.10.3405
250. Beatty GL, Paterson Y. IFN-gamma can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen. J Immunol (2000) 165:5502–8. doi:10.4049/jimmunol.165.10.5502
251. Brocker EB, Zwadlo G, Holzmann B, Macher E, Sorg C. Inflammatory cell infiltrates in human melanoma at different stages of tumor progression. Int J Cancer (1988) 41:562–7. doi:10.1002/ijc.2910410415
252. Garbe C, Krasagakis K, Zouboulis CC, Schroder K, Kruger S, Stadler R, et al. Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype. J Invest Dermatol (1990) 95:231S–7S. doi:10.1111/1523-1747.ep12875837
253. Brody JR, Costantino CL, Berger AC, Sato T, Lisanti MP, Yeo CJ, et al. Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle (2009) 8:1930–4. doi:10.4161/cc.8.12.8745
254. Cripps JG, Wang J, Maria A, Blumenthal I, Gorham JD. Type 1 T helper cells induce the accumulation of myeloid-derived suppressor cells in the inflamed Tgfb1 knockout mouse liver. Hepatology (2010) 52:1350–9. doi:10.1002/hep.23841
255. Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC, Benninger K, Khan M, Kuppusamy P, et al. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res (2011) 71:5101–10. doi:10.1158/0008-5472.CAN-10-2670
256. Abiko K, Mandai M, Hamanishi J, Yoshioka Y, Matsumura N, Baba T, et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res (2013) 19:1363–74. doi:10.1158/1078-0432.CCR-12-2199
257. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med (2016) 375:819–29. doi:10.1056/NEJMoa1604958
258. Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov (2017) 7:188–201. doi:10.1158/2159-8290.CD-16-1223
259. Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell (2016) 167:1540–54.e12. doi:10.1016/j.cell.2016.11.022
260. Wang XB, Zheng CY, Giscombe R, Lefvert AK. Regulation of surface and intracellular expression of CTLA-4 on human peripheral T cells. Scand J Immunol (2001) 54:453–8. doi:10.1046/j.1365-3083.2001.00985.x
261. Creagan ET, Ahmann DL, Long HJ, Frytak S, Sherwin SA, Chang MN. Phase II study of recombinant interferon-gamma in patients with disseminated malignant melanoma. Cancer Treat Rep (1987) 71:843–4.
262. Ernstoff MS, Trautman T, Davis CA, Reich SD, Witman P, Balser J, et al. A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma. J Clin Oncol (1987) 5:1804–10. doi:10.1200/JCO.1987.5.11.1804
263. Kopp WC, Smith JW II, Ewel CH, Alvord WG, Main C, Guyre PM, et al. Immunomodulatory effects of interferon-gamma in patients with metastatic malignant melanoma. J Immunother Emphasis Tumor Immunol (1993) 13:181–90. doi:10.1097/00002371-199304000-00005
264. Khorana AA, Rosenblatt JD, Sahasrabudhe DM, Evans T, Ladrigan M, Marquis D, et al. A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma. Cancer Gene Ther (2003) 10:251–9. doi:10.1038/sj.cgt.7700568
265. Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad F, et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med (1998) 338:1265–71. doi:10.1056/NEJM199804303381804
266. Talpaz M, Kurzrock R, Kantarjian H, Rothberg J, Saks S, Evans L, et al. A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia. Cancer (1991) 68:2125–30. doi:10.1002/1097-0142(19911115)68:10<2125::AID-CNCR2820681006>3.0.CO;2-Q
267. Von Hoff DD, Fleming TR, Macdonald JS, Goodman PJ, Van Damme J, Brown TD, et al. Phase II evaluation of recombinant gamma-interferon in patients with advanced pancreatic carcinoma: a Southwest Oncology Group study. J Biol Response Mod (1990) 9:584–7.
268. Vahdat LT, Cohen DJ, Zipin D, Lo KS, Donovan D, Savage D, et al. Randomized trial of low-dose interleukin-2 vs cyclosporine A and interferon-gamma after high-dose chemotherapy with peripheral blood progenitor support in women with high-risk primary breast cancer. Bone Marrow Transplant (2007) 40:267–72. doi:10.1038/sj.bmt.1705692
269. Wiesenfeld M, O’Connell MJ, Wieand HS, Gonchoroff NJ, Donohue JH, Fitzgibbons RJ Jr, et al. Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer. J Clin Oncol (1995) 13:2324–9. doi:10.1200/JCO.1995.13.9.2324
270. Alberts DS, Marth C, Alvarez RD, Johnson G, Bidzinski M, Kardatzke DR, et al. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Gynecol Oncol (2008) 109:174–81. doi:10.1016/j.ygyno.2008.01.005
271. Kim OY, Park HT, Dinh NTH, Choi SJ, Lee J, Kim JH, et al. Bacterial outer membrane vesicles suppress tumor by interferon-gamma-mediated antitumor response. Nat Commun (2017) 8:626. doi:10.1038/s41467-017-00729-8
272. Kim JS, Park YM, Kim NY, Yun HK, Lee KJ, Kim BH, et al. Combination treatment with intrahepatic arterial infusion and intratumoral injection chemotherapy in patients with far-advanced hepatocellular carcinoma and arterioportal or arteriovenous shunts: preliminary results. Korean J Hepatol (2011) 17:120–9. doi:10.3350/kjhep.2011.17.2.120
273. Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol (2017) 14(12):717–34. doi:10.1038/nrclinonc.2017
274. Estrov ZKR, Talpaz M. Interferons: Basic Principles and Clinical Applications. Portland: Book News, Inc. (1993).
275. Razaghi A, Owens L, Heimann K. Review of the recombinant human interferon gamma as an immunotherapeutic: impacts of production platforms and glycosylation. J Biotechnol (2016) 240:48–60. doi:10.1016/j.jbiotec.2016.10.022
276. Kurzrock R, Rosenblum MG, Sherwin SA, Rios A, Talpaz M, Quesada JR, et al. Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. Cancer Res (1985) 45:2866–72.
277. Devane JG, Martin ML, Matson MA. A short 2 week dose titration regimen reduces the severity of flu-like symptoms with initial interferon gamma-1b treatment. Curr Med Res Opin (2014) 30:1179–87. doi:10.1185/03007995.2014.899209
278. van Loon AP, Ozmen L, Fountoulakis M, Kania M, Haiker M, Garotta G. High-affinity receptor for interferon-gamma (IFN-gamma), a ubiquitous protein occurring in different molecular forms on human cells: blood monocytes and eleven different cell lines have the same IFN-gamma receptor protein. J Leukoc Biol (1991) 49:462–73. doi:10.1002/jlb.49.5.462
279. Valente G, Ozmen L, Novelli F, Geuna M, Palestro G, Forni G, et al. Distribution of interferon-gamma receptor in human tissues. Eur J Immunol (1992) 22:2403–12. doi:10.1002/eji.1830220933
280. Bello I, Perez A, Torres AM, Hernandez MV, Lopez Saura P. High levels of soluble IFN gamma receptor alpha chain in the plasma of rheumatoid arthritis patients. Biotherapy (1998) 11:53–7. doi:10.1023/A:1008087100315
281. Nathan CF, Kaplan G, Levis WR, Nusrat A, Witmer MD, Sherwin SA, et al. Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. N Engl J Med (1986) 315:6–15. doi:10.1056/NEJM198607033150102
282. Edwards L, Whiting D, Rogers D, Luck K, Smiles KA. The effect of intralesional interferon gamma on basal cell carcinomas. J Am Acad Dermatol (1990) 22:496–500. doi:10.1016/0190-9622(90)70070-X
283. Thom AK, Fraker DL, Taubenberger JK, Norton JA. Effective regional therapy of experimental cancer with paralesional administration of tumour necrosis factor-alpha + interferon-gamma. Surg Oncol (1992) 1:291–8. doi:10.1016/0960-7404(92)90090-8
284. Lejeune F, Lienard D, Eggermont A, Schraffordt Koops H, Rosenkaimer F, Gerain J, et al. Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma. J Cell Biochem (1994) 56:52–61. doi:10.1002/jcb.240560110
285. Sokoloff MH, Tso CL, Kaboo R, Taneja S, Pang S, deKernion JB, et al. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Cancer (1996) 77:1862–72. doi:10.1002/(SICI)1097-0142(19960501)77:9<1862::AID-CNCR16>3.0.CO;2-Y
286. Habif DV, Ozzello L, De Rosa CM, Cantell K, Lattes R. Regression of skin recurrences of breast carcinomas treated with intralesional injections of natural interferons alpha and gamma. Cancer Invest (1995) 13:165–72. doi:10.3109/07357909509011686
287. Weiss JM, Muchenberger S, Schopf E, Simon JC. Treatment of granuloma annulare by local injections with low-dose recombinant human interferon gamma. J Am Acad Dermatol (1998) 39:117–9. doi:10.1016/S0190-9622(98)70412-8
288. Bocci V. Roles of interferon produced in physiological conditions. A speculative review. Immunology (1988) 64:1–9.
289. Younes HM, Amsden BG. Interferon-gamma therapy: evaluation of routes of administration and delivery systems. J Pharm Sci (2002) 91:2–17. doi:10.1002/jps.10007
290. Hayakawa M, Hatano T, Miyazato T, Sato K, Saito S, Osawa A, et al. [Studies on the antitumor effects of human interferon (2). Effects of massive pulsatile administration of rIFN-gamma on advanced renal cell carcinoma]. Nihon Hinyokika Gakkai Zasshi (1987) 78:1784–91.
291. Murray HW. Effect of continuous administration of interferon-gamma in experimental visceral leishmaniasis. J Infect Dis (1990) 161:992–4. doi:10.1093/infdis/161.5.992
292. Cantell K, Hirvonen S, Pyhala L, De Reus A, Schellekens H. Circulating interferon in rabbits and monkeys after administration of human gamma interferon by different routes. J Gen Virol (1983) 64(Pt 8):1823–6. doi:10.1099/0022-1317-64-8-1823
293. Levine RU, Crum CP, Herman E, Silvers D, Ferenczy A, Richart RM. Cervical papillomavirus infection and intraepithelial neoplasia: a study of male sexual partners. Obstet Gynecol (1984) 64:16–20.
294. Gross G, Roussaki A, Papendick U. Efficacy of interferons on bowenoid papulosis and other precancerous lesions. J Invest Dermatol (1990) 95:152S–7S. doi:10.1111/1523-1747.ep12875145
295. Hautmann SH, Huland E, Huland H. Local intratumor immunotherapy of prostate cancer with interleukin-2 reduces tumor growth. Anticancer Res (1999) 19:2661–3.
296. Zhao Z, Leong KW. Controlled delivery of antigens and adjuvants in vaccine development. J Pharm Sci (1996) 85:1261–70. doi:10.1021/js9602812
297. van Slooten ML, Storm G, Zoephel A, Kupcu Z, Boerman O, Crommelin DJ, et al. Liposomes containing interferon-gamma as adjuvant in tumor cell vaccines. Pharm Res (2000) 17:42–8. doi:10.1023/A:1007514424253
298. Mejias R, Perez-Yague S, Gutierrez L, Cabrera LI, Spada R, Acedo P, et al. Dimercaptosuccinic acid-coated magnetite nanoparticles for magnetically guided in vivo delivery of interferon gamma for cancer immunotherapy. Biomaterials (2011) 32:2938–52. doi:10.1016/j.biomaterials.2011.01.008
299. Segura S, Gamazo C, Irache JM, Espuelas S. Gamma interferon loaded onto albumin nanoparticles: in vitro and in vivo activities against Brucella abortus. Antimicrob Agents Chemother (2007) 51:1310–4. doi:10.1128/AAC.00890-06
300. Ando M, Takahashi Y, Yamashita T, Fujimoto M, Nishikawa M, Watanabe Y, et al. Prevention of adverse events of interferon gamma gene therapy by gene delivery of interferon gamma-heparin-binding domain fusion protein in mice. Mol Ther Methods Clin Dev (2014) 1:14023. doi:10.1038/mtm.2014.23
301. Badea I, Virtanen C, Verrall RE, Rosenberg A, Foldvari M. Effect of topical interferon-gamma gene therapy using gemini nanoparticles on pathophysiological markers of cutaneous scleroderma in Tsk/+ mice. Gene Ther (2012) 19:978–87. doi:10.1038/gt.2011.159
302. Bourgeois-Daigneault MC, Roy DG, Falls T, Twumasi-Boateng K, St-Germain LE, Marguerie M, et al. Oncolytic vesicular stomatitis virus expressing interferon-gamma has enhanced therapeutic activity. Mol Ther Oncolytics (2016) 3:16001. doi:10.1038/mto.2016.1
303. Zanganeh S, Hutter G, Spitler R, Lenkov O, Mahmoudi M, Shaw A, et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat Nanotechnol (2016) 11:986–94. doi:10.1038/nnano.2016.168
304. van Broekhoven CL, Parish CR, Demangel C, Britton WJ, Altin JG. Targe-ting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res (2004) 64:4357–65. doi:10.1158/0008-5472.CAN-04-0138
305. Cruz LJ, Rosalia RA, Kleinovink JW, Rueda F, Lowik CW, Ossendorp F. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study. J Control Release (2014) 192:209–18. doi:10.1016/j.jconrel.2014.07.040
306. Castro F, Pinto ML, Silva AM, Pereira CL, Teixeira GQ, Gomez-Lazaro M, et al. Pro-inflammatory chitosan/poly(gamma-glutamic acid) nanoparticles modulate human antigen-presenting cells phenotype and revert their pro-invasive capacity. Acta Biomater (2017) 63:96–109. doi:10.1016/j.actbio.2017.09.016
307. Kumar M, Coburn J, Kaplan DL, Mandal BB. Immuno-informed 3D silk biomaterials for tailoring biological responses. ACS Appl Mater Interfaces (2016) 8:29310–22. doi:10.1021/acsami.6b09937
Keywords: type II interferon, immunoregulation, cancer microenvironment, immunotherapy, immune contexture
Citation: Castro F, Cardoso AP, Gonçalves RM, Serre K and Oliveira MJ (2018) Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion. Front. Immunol. 9:847. doi: 10.3389/fimmu.2018.00847
Received: 06 December 2017; Accepted: 05 April 2018;
Published: 04 May 2018
Edited by:
Fabrizio Mattei, Istituto Superiore di Sanità, ItalyReviewed by:
Alexandre Corthay, Oslo University Hospital, NorwayChristine Susanne Falk, Hannover Medical School, Germany
Copyright: © 2018 Castro, Cardoso, Gonçalves, Serre and Oliveira. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Maria José Oliveira, mariajo@ineb.up.pt